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The advent of cosmeceuticals and modern drug discovery techniques has 
generated extensive research in botanicals to develop health-promoting 
cosmeceutical products. However, most of these botanicals with high 
therapeutic potential are poorly water-soluble. Additionally, the skin barrier 
poses a biological obstacle to cosmeceutical products. Hence, it is a great 
challenge to present and deliver these molecules and achieve adequate 
bioavailability. One attractive approach to improve the percutaneous 
absorption and bioavailability of cosmeceuticals is to formulate them in a 
nanoemulsion delivery system. In this work, an innovative delivery system 
(oil-in-water nanoemulsion) capable of penetrating into the deeper skin layers 
(transdermal delivery) was developed for a novel cosmeceutical ingredient 
(schizandrol A). Clean and green strategies, encompassing minimization of 
surfactant amount, use of inexpensive, nontoxic and environment-friendly 
solvent, and biodegradable compounds in support of sustainable materials 
were implemented. 
The intrinsic physicochemical properties of schizandrol A were first 
examined to establish the preformulation characterization profile. Next, 
components of the nanoemulsion were selected based on solubility and 
compatibility studies. Solubilization methods, namely micellization, 
cosolvency and complexation, were proposed to improve the aqueous 
solubility of schizandrol A. The solubility capacity of these systems was 
studied both individually and in combination. Sucrose laurate exhibited the 
highest solubilization capacity in this study and was chosen as the main 
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surfactant in the nanoemulsion formulation. The cosurfactant was selected 
based on compatibility with schizandrol A. Ethyl butanoate was found to be 
the most effective oil to solubilize schizandrol A and was therefore selected 
for subsequent nanoemulsion formation. 
Phase behavior was examined to study the potential of using selected 
components to develop the nanoemulsion. The effects of cosurfactants and Sm 
ratios were investigated. Based on the pseudo-ternary phase diagrams, a 
surfactant to cosurfactant weight ratio (Sm) of 1:1 was selected. 
The nanoemulsion was prepared using the high pressure homogenization 
method. Impact of the homogenizer operating pressure and number of 
homogenization passes, concentration of oil and surfactant, and the type of 
cosurfactant were studied respectively. Droplet size and polydispersity index 
were used to evaluate the efficiency of the nanoemulsion preparation. 
Schizandrol A was subsequently incorporated to the successful nanoemulsion 
formulations. 
The particle size analysis by dynamic light scattering (DLS) method 
demonstrated the droplets of formulated nanoemulsions were in the nano 
range, which was further confirmed by the microstructure studies using 
electron microscopes. Formulated nanoemulsions containing schizandrol A 
were subjected to a variety of stability tests. Schizandrol A loaded 
nanoemulsions were stable under the tested conditions up to 30 days. Based on 
in vitro permeation studies using a synthetic membrane, schizandrol A loaded 
nanoemulsion formulations displayed improved percutaneous absorption than 
water-ethanol (1:1, v/v) mixed solvent. 
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The present work has important implications in the design of effective 
delivery systems for lignans and other hydrophobic active ingredients intended 
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CHAPTER 1 INTRODUCTION 
 
1.1 Overview 
Cosmeceuticals and nutraceuticals have become a prime focus in the 
health and well-being market nowadays, bolstered by the growing population 
of health-conscious consumers. Botanicals are the main and most abundant 
sources for potential cosmeceutical and nutraceutical products. 
Schizandrol A is a natural lignan component derived from Schisandra 
chinensis, in which its extract has a long history of being consumed as food 
and traditional Chinese medicine (TCM) (Hanckea et al., 1999; Panossian and 
Wikman, 2008). Based on modern pharmacological studies, schizandrol A has 
been found to possess multi-pharmacological benefits including anti-oxidant, 
anti-inflammatory, anti-proliferative and anti-viral effects (Guo et al., 2008; 
Min et al., 2008; Panossian and Wikman, 2008; Sun et al., 2011). Despite 
these marked biological activities, the application of schizandrol A is hindered 
by its low bioavailability via the oral route due to its poor water solubility and 
first pass metabolism (Niu et al., 1983; Xu et al., 2006). Transdermal delivery 
is therefore a potential advantageous alternative route. 
Formulating a nanoemulsion is one of the most promising strategies to 
tackle these problems. The advantages of a nanoemulsion delivery system 
include reduced toxicity and irritant potency, improved consumer compliance, 
enhanced absorption and prolonged stability (Devarajan and Ravichandran, 
2011; McClements and Rao, 2011; Sonneville-Aubrun et al., 2004). An oil-in-
water nanoemulsion can increase the apparent aqueous solubility of 
hydrophobic bioactive ingredients. The higher concentration of active 
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ingredient in the formulation and other nanoemulsion components such as 
emulsifiers and oil phase all facilitate active ingredient permeation across the 
skin. Therefore, a nanoemulsion delivery system, with enhanced schizandrol A 
solubility, is a desirable approach to improve its bioavailability for 
applications in personal care and health. 
The present work involves formulation design, development and 
characterization of nanoemulsions containing schizandrol A to overcome the 
challenges faced during product development. Systematic screening of process 
parameters and formulation variables was carried out to optimize the delivery 
system. Characterization on physicochemical properties , stability studies and 
in vitro permeation test were conducted for the proposed nanoemulsion 
formulations to demonstrate their potential to be used as cosmeceutical 
product. 
 
1.2 Background and Significance 
The word “cosmeceutical” was coined in the late 20th century, and since 
then, they have been extensively investigated and developed into products, 
driven by an increasing consumer demand worldwide. 
Botanicals represent a major class of cosmeceuticals. They are generally 
regarded as a plentiful natural source of antioxidant and anti-inflammatory 
agents. A diverse range of botanicals have been applied in personal care 
formulations (Barker, 1995; Bissett, 2009). The advances in nanotechnology 
promote the development of scientifically innovative cosmeceutical products. 
However, for a large number of active ingredients in commercialized 
cosmeceutical products there is a lack of penetration data, a lack of 
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understanding of their biological mechanisms and little clinical data. Therefore, 
it is necessary to understand these chemical entities and investigate the 
performance of end products made from them. 
The delivery of botanicals is complicated by problems such as inadequate 
aqueous solubility, low bioavailability and efficacy, poor physical stability and 
adverse effects of active ingredients. Thus, novel biocompatible nanoemulsion 
delivery systems via the topical route are developed to enhance percutaneous 
absorption, increase the efficacy, reduce the level of dosage, and decrease the 
incidence and severity of adverse effects. 
Schizandrol A is a typical lignan compound with a variety of biological 
benefits. However, there are no available developed products for its delivery. 
Therefore, a novel carrier system for schizandrol A as the cosmeceutical active 
ingredient is of both theoretical and practical significance. The motivation of 
this work is to lead towards commercialization of a nanoemulsion containing 
schizandrol A and scale-up production to fulfill its unique and valuable 
pharmacological properties. Moreover, it may be a spur to the development of 
lignan-based products. 
 
1.3 Objectives and Scope of Study 
The ultimate goal of the present work is to design and develop 
nanoemulsion-based delivery system intended for transdermal delivery of 
schizandrol A. 
More specifically, the aims are: 




Physicochemical properties of schizandrol A will be examined, 
focusing on elemental, phase and thermal analysis. Solubility of 
schizandrol A in a number of aqueous and oil phases will be tested to 
select efficient solubilizing agents and oil phase for subsequent 
formulation. 
2. Evaluating the compatibility of selected components and rationality of 
compositions. 
Formulation components and compositions selected will be used to 
prepare nanoemulsion by a high pressure homogenization process to 
assess their feasibility and efficiency. 
3. Optimizing process parameters and formulation variables for nanoemulsion 
preparation. 
Key properties of nanoemulsion will be characterized to optimize the 
process parameters. Optimum compositions will be determined by 
their efficiency of nanoemulsion formation. Schizandrol A loaded 
nanoemulsion will be prepared based on the developed experimental 
conditions and composition. 
4. Evaluating the potential of developed nanoemulsion formulations for 
transdermal application. 
Schizandrol A loaded nanoemulsion formulations will be subjected to 
various stability tests. The percutaneous absorption of schizandrol A 
will be evaluated using Franz diffusion cell tests with a synthetic 
membrane. A water-ethanol binary solution containing the same 




1.4 Organization of the Thesis 
This thesis shows how a nanoemulsion with good stability and 
performance is developed for a cosmeceutical ingredient. The organization of 
this thesis is as follows. Chapter 1 provides the overview, motivation, 
objectives of the present work and outline of the main body. 
In chapter 2, a literature survey is presented with respect to all key words 
in this thesis. The term “cosmeceutical” is the most important principle in this 
thesis. It is explained by comparison to the conventional concept of 
“pharmaceutical”. How schizandrol A fits into this overall scheme of 
cosmeceutical science is described. Three main routes of administration are 
discussed. The transdermal route is highlighted with scientific and 
technological aspects of design and development of delivery systems. The 
structure of human skin and barrier properties are briefly introduced. Modern 
delivery systems are discussed with specific considerations, namely 
physicochemical properties of bioactive ingredient, interaction between 
formulation components and how the administration route affects the 
absorption.  Nanoemulsion as proposed delivery system is discussed in detail. 
The main components and approaches to nanoemulsion formation are 
discussed. The limitations and formulation challenges are discussed regarding 
each key word. 
Chapter 3 provides experimental themes describing the steps to which 
schizandrol A is subjected towards the end of product development. First, 
experimental materials are listed with their sources. Experimental design 
illuminates the rationale for  steps in the nanoemulsion formulation, selection 
of components and composition, and characterization methods employed. 
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Factors and levels of experiments are listed. Experimental methods described 
in this chapter are in the same order of steps in the experimental design. 
Statistical methods used for data analysis  are explained. 
Chapter 4 is the section of results and discussion. The arrangement of 
findings displayed is in accordance with the experimental design described in 
chapter 3. The experimental results are discussed with regard to each subtitle. 
Impacts of process parameters and formulation variables are discussed. The 
results are interpreted in terms of scientific principles. 
Chapter 5 summaries the conclusions and contributions of the present 
work. The objectives of this thesis were successfully achieved. This thesis is 
the first to report schizandrol A loaded oil-in-water nanoemulsion 
formulations with enhanced percutaneous absorption and good stability. The 
results demonstrate that it is nanoemulsion is a suitable delivery system of 
schizandrol A providing a promising potential for a cosmeceutical product 
through topical application. 
Chapter 6 points out the limitations of current studies and proposes the 
recommendations for future research.  
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 Cosmeceuticals 
Cosmeceuticals are devoted to health and aesthetic concerns and have 
considerable consumer interest. Functions and appearance of the skin can 
deteriorate due to minor defects induced by environmental exposure 
accumulated over time, and cosmeceutical products are therefore developed to 
address these issues. Many studies on cosmeceuticals form a link to the study 
of complementary medicines of natural origins. Although there are still 
worldwide debates over how cosmeceuticals should be explicitly defined, with 
a better understanding on the structure and function of human skin and body, 
intelligent cosmeceutical products can be devised (Epstein, 2009a; Morganti et 
al., 2001; Tsujimoto and Hara, 2012). 
2.1.1 Emergence of cosmeceuticals 
The topics of cosmeceuticals and nutraceuticals are of the hottest issues in 
the field of personal care and well-being today. There is a growing need for 
emphasis on linking nutrition and long-term health. Nutraceuticals are the oral 
counterpart of cosmeceuticals. Substantial and rapid growth in cosmeceuticals 
and nutraceuticals industry has ripened for a market where they are no long 
regarded as inexpensive “snake oil”. The realm of cosmeceuticals and 
nutraceuticals are rapidly expanding the area of pharmaceuticals. The 
emergence of cosmeceuticals also challenges the clear distinction between a 
cosmetic and a drug. 
Pharmaceuticals have been traditionally classified as a compound 
manufactured for use as a medicinal drug. The Federal Food, Drug, and 
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Cosmetic Act (FD&C Act) defines drugs as “articles intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles 
(other than food) intended to affect the structure or any function of the body of 
man or other animals” [FD&C Act, sec. 201(g)(1)]. 
An active pharmaceutical ingredient (API) is defined by ICH Q7A as 
“any substance or mixture of substances intended to be used in the 
manufacture of a drug product and that, when used in the production of a drug, 
becomes an active ingredient in the drug product. Such substances are 
intended to furnish pharmacological activity or other direct effect in the 
diagnosis, cure, mitigation, treatment or prevention of disease or to affect the 
structure and function of the body…US FDA and industry use terms like 
“drug substance” and “bulk pharmaceutical chemical” (BPC) to refer to an 
API and excipients where BPC refers to inactive ingredients” (FDA, 2001). 
The active ingredient is defined as “any component that provides 
pharmacological activity or other direct effect in the diagnosis, cure, 
mitigation, treatment, or prevention of disease, or to affect the structure or any 
function of the body of man or animals.” by U.S. Food and Drug 
Administration (FDA) (FDA, 2012). 
Cosmetics have been around for centuries. The term “cosmetics” has been 
defined by the FD&C Act as " (1) articles intended to be rubbed, poured, 
sprinkled, or sprayed on, introduced into, or otherwise applied to the human 
body or any part thereof for cleansing, beautifying, promoting attractiveness, 
or altering the appearance, and (2) articles intended for use as a component of 




“Cosmeceutical” is the linguistic fusion of “cosmetic” and 
“pharmaceutical” coined by Professor Albert Kligman (1993) indicating the 
expected bioactivity of the cosmetic product. Cosmeceuticals fit somewhere 
between cosmetics and drugs such that a substance will achieve cosmetic 
benefits by means of physiological action. Cosmeceuticals are designed to 
supplement the efficacy of pharmaceuticals, enhance patient compliance 
(application, feel, smell, etc.), and provide skin benefits. They have specific 
roles in skin protection and anti-aging processes (Lintner et al., 2009). 
Presently, cosmeceuticals addressed “biologically active ingredients” are 
increasingly being used in place of or in addition to medical procedures. They 
feature more prominently in the practice of dermatology (Draelos, 1999; 
Markarian and Hovsepian, 2011; Paul, 2009). 
Cosmeceuticals are at the grey area of regulation worldwide and thus 
under constant controversy, whereas they are already acknowledged by the 
consumer and market (Brandt et al., 2011; Millikan, 2001; Rosholt, 2008). 
The FD&C Act does not recognize any such category as “cosmeceuticals” or 
“nutraceuticals”. FDA states that “A product can be a drug, a cosmetic, or a 
combination of both, but the term "cosmeceutical" has no meaning under the 
law.” (FDA, 2012). Nowadays, both cosmeceuticals and nutraceuticals are 
unregulated categories of ingredients that fit into the over-the-counter (OTC) 
products category. 
To articulate the boundaries and overlaps of cosmeceutical, nutraceutical 
and pharmaceutical realms, it is necessary to start from their intended use. In 
principle, cosmeceutical products do not replace prescription therapy. They 
are useful in the maintenance phase of disease treatment for conditions, 
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providing barrier enhancement, representing an important adjuvant for 
reducing inflammation, and maintaining an optimal appearance (Amer and 
Maged, 2009). Cosmeceuticals are supposed to penetrate the stratum corneum 
barrier more deeply than a conventional cosmetic ingredient to exert biological 
effects. However, they remain at a level where will not intrude into drug realm. 
The objectives of pharmaceuticals are aimed at treatment of disease, while 
cosmeceuticals and nutraceuticals are primarily directed toward reducing risk 
of diseases, increasing resistance to disease, and health enhancement. 
Nonetheless, research methods established so far for pharmaceuticals can 
preferably implement product development for cosmeceuticals. Furthermore, 
it has been reported that the combination of pharmaceuticals with 
cosmeceuticals not only increases disease control but also encourages patient 
compliance with additional benefits (Amer and Maged, 2009). 
Botanicals, vitamins, lipids, moisturizers, metals, exfoliants, peptides, 
antioxidants, growth factors, sunscreens are general categories of 
cosmeceuticals (Choi and Berson, 2006; Draelos, 2011). Botanicals are often 
regarded as natural safer alternatives to their synthetic counterparts by 
consumers (Chanchal and Swarnlata, 2008). Among botanicals, there are three 
main categories: antioxidant, anti-inflammatory and soothing agent. 
Cosmeceutical products typically take the form of cream, lotion, serum 
and solution. It is reported that there is a trend in dermatological 
pharmaceutical companies expanding their offerings to include 
complementary cosmeceutical skin care products, co-package pharmaceutical 
and cosmeceutical formulations (Brandt et al., 2011; Wilson, 2008). This 
practice further merges the concepts of pharmaceuticals and cosmeceuticals. 
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2.1.2 Limitations and formulation challenges of cosmeceuticals 
The development of cosmeceuticals closely parallels pharmaceutical 
research. Safety, efficacy and compliance are three categories of concern for 
any health product. The developed formulation must perform well in each 
regard. 
At the initial stage, the identity and purity of the active ingredient is the 
first concern. It is worthwhile to give the active ingredient in its chemical 
nomenclature (Chemical Abstract Service, CAS) or Latin rather than common 
name, to avoid confusion. Using the common name to represent the active 
substance may raise confusion or even cause fatal problems (Varner, 2001; 
Zhao et al., 2006). For instance, a carcinogen and nephrotoxic compound, 
aristolochic acid was unintentionally introduced into a product in Belgium 
(1993) and in UK (1999) because of the confusion of ingredients, where 
Guang Fang Ji (root of Aristolochia fangchi) was substituted for Fang Ji (root 
of Stephania tetrandar), and Guan Mu Tong (stem of Aristolochia 
manshuriensis) for Chuan Mu Tong (stem of Clematis armandii) and Mu 
Tong (stem of Akebia sp.), respectively (Lachance and Das, 2007). 
Questions arise in the area of cosmeceuticals essentially in the view of 
safety and claims of the product in the market (Lintner, 2009; Nohynek et al., 
2010; Schroeder, 2009b). The risk-benefit relation should be well studied 
because there is no limit of intake for cosmeceuticals derived from natural 
sources, which food or medical prescription can provide. This brings about the 
danger of bioactive ingredient “overdose” being ingested or transported. In 
addition, numerous cosmeceuticals are hydrophobic substances which limit 
the absorption due to the poor water solubility. This requires a larger amount 
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of cosmeceuticals to be consumed in order to achieve health benefits. 
Moreover, some active substances can be expensive and use of high amount is 
a draw-back because of the consequent high cost. As a result, an efficient 
delivery system is desirable to minimize the amount of active substance 
without lowering the efficacy. 
Furthermore, there is a general believe that substances safe for oral 
consumption are also safe for topical application. Though this is mostly true, 
contact dermatitis can occur in sensitized individuals from cosmeceuticals 
otherwise known as safe via the oral route (Barrientos et al., 2012; Groot, 
1997). To eliminate these problems, a thorough investigation of its toxicity 
profile of a cosmeceutical ingredient for intended use is necessary. 
Whether cosmeceuticals can indeed significantly contribute to health, or 
truly fulfill the claimed benefits is another important question (Lin, 2010). 
There is a misconception among consumers that bioactive substances defined 
as healthy are able to provide real efficacy. In fact, there is a possibility that 
bioactive substances function in a completely different way when they are 
isolated from their natural environment (Draelos, 2008b). Besides, synergistic 
effects occurring in the bulk matrix may influence the performance of the 
bioactive substance. Hence, it is crucial to investigate the bioactive substances 
under proposed application conditions. 
The final success of cosmeceutical product strongly depends on two 
factors—the aesthetics of the formulation and the performance of the product. 
The aesthetics (color, odor, feel, application, etc.) are the properties of a 
formulation that determine whether the consumer will continue to use the 
formulation as directed. Performance, fulfillment of the claimed benefits, is 
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the other part. The formulation of the delivery system is intended to maximize 
the performance of the active ingredient with consumer-perceivable benefits. 
The delivery system is designed to deliver the claimed benefits in the shortest 
period of time or long term required by the consumer. They also serve to 
protect the active ingredient and help to stabilize the ingredient as well as the 
whole product. Thus, formulation considerations cover both activity and 
stability of the active ingredient and the matrix. 
The health benefit relies on the bioavailability of cosmeceuticals. 
Bioavailability refers to the rate and extent to which a substance is adsorbed in 
a living system and is made available at the site of physiological activity 
(Atkinson, 2007). 100% bioavailability of molecule is achieved via the 
intravenous route, and decreases by the other routes (e.g. orally, topically) due 
to various barriers. The ability of an active ingredient to realize its biological 
function depends on the formulation design that can maintain the integrity and 
deliver the ingredient to the target site in sufficient quantity and finally release 
it properly to exert an effect. 
The primary problem for most nature-derived active ingredients is their 
poor aqueous solubility. Poor solubility limits the adsorption rate in living 
organisms resulting in low bioavailability. To address this problem, 
preformulation techniques (e.g. chemical modification) and formulation 
strategies have been explored. However, not all nature-derived compounds are 
amenable to chemical modifications, not to mention, enormous cost and time 
consuming toxicological studies are necessary when a chemically modified 
entity has to be registered. 
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Working with formulation strategies presents two substantial challenges. 
First of all, components in the delivery system must be compatible with each 
other and more importantly with the active substance. It is essential to ensure 
all ingredients being functional within the parameters of the formulation to 
maximize the benefits that are to be obtained from these materials. In addition, 
bioactivity, mode of action, and absorption also need to be understood so as to 
select the most suitable formulation components. 
Secondly, instabilities (e.g. hydrolysis, photolysis) may be caused by the 
environment (e.g. heat, light, moisture, pH, and oxidation). For example, 
formulation in the pH range of 4 to 7 is preferred to avoid hydrolysis. Low pH 
can lead to unwanted aesthetic skin effects. To improve or maintain the 
stability of cosmeceuticals in the formulation, components insensitive to 
temperature or light are preferable. 
In conclusion, a high quality, stable, efficacious cosmeceutical 
formulation is determined by the selection of the delivery route, a suitable 
delivery system, and the integrity of the matrix. 
2.1.3 Schizandrol A as a cosmeceutical ingredient 
Botanicals have become the largest category of cosmeceuticals in the 
market today, owing to the strong driving force in the cosmetic industry 
toward natural products (Burdock et al., 2006; Morganti, 2009). Plant extracts 
from roots, stems, leaves, fruits, berries, twigs, barks and flowers can be 
encompassed in cosmetic formulations. 
Schisandra chinensis (Turcz.) Baill (Schisandraceae family) is a woody 
vine (liana) with climbing branches. It is widely distributed throughout 
northern and northeast China, Korea, Japan, and Russia. Its fruit has a unique 
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taste that combines sweet, salty, sour, bitter and spicy. Schisandra has a long 
history of being used as a health-promoting and stimulating tonic, in the same 
class with Ginseng and Ganoderma (Liu, 1989; Opletal et al., 2004). 
Shengmaisan is a classical traditional Chinese medicine prescription 
consisting of Schisandra chinensis fruit, Panax ginseng and Ophiopogonis 
japonicus (Tao et al., 2003; Xu et al., 2008b). Shengmaisan has a synergistic 
effect for qi and yin deficiency in TCM theory and was found to have effect 
on heart failure, anti-cancer and anti-fatigue activities (Chen et al., 2007; Lo et 
al., 2012). 
Schisandra has been served as a beauty tonic to make skin soft, moist and 
radiant due to its excellent astringent quality. Studies have shown that 
biological activities of schisandra are mainly attributed to lignans (Figure 2.1) 
which possess marked antioxidant, adaptogenic and hepatoprotective 
properties (Hanckea et al., 1999; Panossian and Wikman, 2008). 
Schizandrins compose the major group of lignans extracted from 
Schisandra. The taxonomic distribution of schizandrins is limited to 
Schisandra. Schizandrins are primarily located in the seeds of the fruit. 
Schizandrol A is the main naturally-occurring derivative of schizandrins. The 
systematic name of schizandrol A is (6S, 7S)-1, 2, 3, 10, 11, 12–hexamethoxy-
6, 7-dimethyl-5, 6, 7, 8-tetrahydrodibenzo [a, c] cycloocten-6-ol and its CAS 
number is 7432-28-2. It has several synonyms namely schizandrin, schisandrin, 
wuweizi spirit A, Wuweizi alcohol A, and Wuweizichun A (Kochetkov et al., 
1961; Panossian and Wikman, 2008). 
Schizandrol A is a dibenzocyclooctadiene lignan possessing a twist-boat-
chair conformation of a cyclooctadiene ring with functional groups: six 
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methoxyl groups on the aromatic rings, two benzylic methylenes, a secondary 
methyl group, and a tertiary methyl group attached to a carbon carrying a 
hydroxyl group (Figure 2.2) (Ikeya et al., 1979). Schizandrol A has a 
molecular formula of C24H32O7 and a molecular weight of 432.5 g/mol. 
Schizandrol A is an odorless, white crystalline substance. It has an estimated 
logP value of 4.08 (EPISuite). 
 
Figure 2.1 Lignan carbon framework. 
 
Figure 2.2 Chemical structure of schizandrol A. 
 
2.1.3.1 Pharmacological activities of schizandrol A 
Antioxidant effect. An excess of active oxygen radicals in the body 
is harmful for health. It damages cell components leading to such diseases as 
tumours, heart and brain damage and especially aging of organs (Droge, 2002). 
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A variety of lignans show anti-oxidant activities. Studies on the scavenging 
effect of schizandrol A on active oxygen radicals produced from human 
polymorphonuclear leukocytes (PMN) stimulated with phorbol myristate 
acetate (PMA) revealed that schizandrol A has a stronger scavenging effect on 
∙OH than that of vitamin E and vitamin C. The scavenging effect of 
schizandrol A on O2 is greater than vitamin E (Zhao et al., 1990). 
Anti-inflammatory effect.  Schizandrol A has been found to exhibit 
good anti-inflammatory effects on carrageenan-induced paw edema and acetic 
acid-induced vascular permeability (inflammation models). It displayed 
protection against LPS-induced sepsis by inhibiting nitric oxide (NO) 
production, prostaglandin E2 (PGE2) release, cyclooxygenase-2 (COX-2) and 
inducible nitric oxide synthase (iNOS) expression. The latter effects result 
from the inhibition of nuclear factor-kappa B (NF-κB), c-Jun N-terminal 
kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) activities in a 
RAW 264.7 macrophage cell line (Guo et al., 2009; Guo et al., 2008). These 
inflammatory mediators have been reported to be associated with many acute 
and chronic inflammatory diseases, such as rheumatoid arthritis and septic 
shock (Boughton-Smith et al., 1993; Chan and Riches, 2001). 
Schizandrol A exhibited therapeutic effect for atopic diseases in the study 
done by Moon and coworkers (2012). In the study, schizandrol A regulated 
inflammatory responses, and inhibited the expression and production of TSLP 
(Thymic stromal lymphopoietin). TSLP plays an important role in allergic 
diseases such as atopic dermatitis, asthma and chronic obstructive pulmonary 
disease. Study of the anti-asthmatic effect of schizandrol A on OVA-induced 
airway inflammation in a murine asthema model indicates that schizandrol A 
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may be an effective therapeutic agent for allergic asthma by reduction of 
oxidative stress and airway inflammation (Lee et al., 2010; Moon et al., 2012). 
Anti-proliferative effect. The inhibitory effect of schizandrol A on 
proliferation has been evaluated in cultured various human cancer cells 
(MDA-MB-231, breast cancer (ER); T47D, breast cancer (ER+); SKHEP-1, 
hepatoma; SNU-638, stomach cancer; HCT-15, colon cancer; K562, leukemia; 
A549, lung cancer) by Min and coworkers (2008). Schizandrol A showed 
effective anti-proliferative activities in the tested cancer cell lines with the IC50 
values ranging 10-70 μm (Min et al., 2008). 
Moreover, the cytotoxicity-related activity of schizandrol A was studied 
on a Ncotiana BY-2 cell model. Šmejkal and coworkers (2010) studied the 
influence of schizandrol A on camptothecin-induced cytotoxicity by 
evaluating toxicity for a colon cancer cell line (LoVo). The results showed that 
schizandrol A significantly inhibited camptothein-induced toxicity after 24, 48 
and 72 h of treatment which indicates its therapeutic effect as 
chemoprotectives, hepatoprotectives or stimulants of the immune response. 
Hepatopotective effect. Schizandrol A was reported to have a strong 
inhibitory effect on the liver damage, protecting the liver from the injury by 
CCl4 and lowers the elevation of GOT and GPT in the serum induced by 
galactosamine (Ko et al., 1995). 
Neuroprotective effect. Cheng and coworkers (2008) investigated the 
neuroprotective effect of schizandrol A on the glutamate (Glu)-induced 
neuronal excitotoxicity using primary cultures of rat cortical cells. Glu 
receptor–mediated toxicity is an important mechanism of neuronal death in 
various pathologic conditions namely ischemia, trauma, epileptic seizures, and 
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neurodegeneration. The study suggests that schizandrol A protected cortical 
cell cultured against Glu-induced apoptosis through a mitochondria-mediated 
pathway and oxidative stress(Cheng et al., 2008). 
Other pharmacological effects. There are also data presented on the 
efficacy of schizandrol A on preventing memory impairment. By enhancing 
cholinergic function, schizandrol A reverses scopolamine-induced memory 
impairment. Schizandrol A (1 and 10 mg/kg, p.o.) significantly reversed the 
scopolamine-induced impairment of spatial memory and 1 mg/kg (p.o.) 
markedly reversed the scopolamine-induced impairment of the passive 
avoidance response (Egashira et al., 2008). Schizandrol A has been studied for 
its anti-HIV activity and results showed that schizandrol A has an EC50 value 
of 15.8 µg/ml, therapeutic index of >12.66 (CC50/EC50) (Sun et al., 2011). 
Maeda and coworkers (1981, 1982) have reported the anti-ulcer effect of 
schizandrol A and its restorative effect on functional depression of the brain. 
Schizandrol A was also reported to improve IgE-induced anaphylaxis and 
scratching behaviors (Lee et al., 2007). 
Toxicity. The acute toxicity for Schisandra chinensis fructus dried extract, 
standardized to a concentration of 2% of schizandrol A was low (LD50>21 
g/kg, p.o.) in rats (Hanckea et al., 1999). Other authors reported the absence of 
lethal effects following intragastric administration of 5 g/kg to mice (Chang 
and But, 2001). 
2.1.3.2 Bioavailability of schizandrol A 
Pharmacokinetic studies have shown that schizandrol A exhibits a 
relatively low bioavailability (Xu et al., 2006; Xu et al., 2005). It is distributed 
widely and eliminated rapidly in rats after oral administration or intravenous 
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injection. After oral administration to rats, schizandrol A was absorbed from 
the gastrointestinal (GI) tract with a half-life of 58 min. After IV injection, 
schizandrol A showed a half-life of the elimination phase of 42 min. 
Schizandrol A was detected in urine 1 h after oral administration (Tang and 
Eisenbrand, 1992). Lu and coworkers (2013) investigated the in vivo behaviors 
of some main components of shengmaisan in rat after oral administration and 
pharmacokinetic results demonstrated that schizandrol A was rapidly absorbed 
in blood, rapidly eliminated after 4 h and near-clearance within 24 h and was 
distributed in the order of small intestine > large intestine > lung > liver > 
kidney > spleen > heart > brain. Schizandrol A was absorbed more rapidly in 
Shengmaisan than administration of pure schizandrol A due to drug-drug 
interaction (Lu et al., 2013). Cytochrome P450 (CYP)-mediated oxidative 
metabolism of schizandrol A was considered as the main clearance route (Cao 
et al., 2010). 
Schisandra lignans such as γ–schizandrin, gomisin A and schizandrin B 
have low oral bioavailability due to poor water solubility (Shao et al., 2010). 
Wang and coworkers (2008) investigated pharmacokinetic profiles of four 
schisandra lignans in rat after oral administration of Schisandra chinensis 
extraction and their results revealed slow distribution and elimination 
processes. The pharmacokinetics and tissue distribution study of schisandrin B 
after oral administration to rats illustrated that schizandrin B was mainly 
accumulated in liver in rats and renal excretion might be a main elimination 




2.2 Transdermal Delivery 
Transdermal delivery refers to the delivery of a bioactive ingredient 
across the skin and into the systemic circulation. The skin is regarded as the 
most efficient barrier preventing absorption of topically administered 
compounds. Percutaneous absorption refers to the transfer of active substance 
from the skin surface into the systemic circulation. The rate and extend of 
percutaneous absorption of cosmeceuticals are affected by the delivery system 
and barrier properties of the skin. 
2.2.1 Routes of administration 
The route of administration is the path by which the bioactive ingredient 
is brought into contact with the body. Routes of administration are typically 
classified by application location (e.g. epicutaneous, subcutaneous, eye, nasal 
etc.) or by the target of action (local or systemic). There are at least 26 
potential routes of medication administration, mainly categorized into oral 
routes, placed into natural orifice in body other than mouth, parenteral, and 
topical routes (Gad, 2009). Each route has its own peculiarities, practical 
considerations and techniques. 
Oral routes consist of oral (p.o.), inhalation, sublingual and buccal route. 
It is the most common, easy, and readily accepted route of drug administration. 
It is easy to measure and administer doses, but sometimes inefficient due to 
incomplete absorption. The main obstacle of the oral route is the first-pass 
effect that restricts the bioactive ingredient reaching the systemic circulation 
by hepatic metabolism. 
Parenteral administration means that the dosage form is injected into the 
body or placed under the skin. It includes three major routes: intravenous (IV), 
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subcutaneous (SC), and intramuscular (IM) route. IV route is frequently used 
to introduce drug directly into the systemic circulation. However, in addition 
to the systemic safety concern, administration by parenteral brings a number 
of special safety issues. Anaphylactic reactions, embolism, hemolysis or 
agglutination of erythrocytes are the possible complications of IV route (Gad, 
2009). 
Topical routes can be classified as cutaneous, transdermal (also called 
percutaneous), and ophthalmic. Topical route has superior local therapeutic 
effects showing lower risk of side effects than other routes, whilst it can also 
be used for systemic delivery. Regarding the topical route, a suitable delivery 
system should contain components with specific activity, function to protect, 
isolate and affect delivery of such components adhesion to the skin or 
penetration through the skin to achieve the best performance. 
The route of administration depends on the characteristics of bioactive 
ingredients, targeted sites, amount and accuracy of the dose, and condition of 
the consumer. Nevertheless, the chosen route of administration will have a 
profound impact on the efficacy of the bioactive ingredient. 
2.2.2 Principles of transdermal delivery 
2.2.2.1 The structure of human skin 
Transdermal delivery fundamentally deals with the skin. Skin is the 
largest organ of the human body that protects against the external material, 
invasion of pathogens, loss of excessive endogenous material such as water, 
and reduces the damaging from external environment (e.g. solar UV radiation). 
Skin is a highly complex, integrated, dynamic and very non-homogenous 
organ that anatomically comprises three main layers: epidermis, dermis and 
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subcutaneous fat layer (hypodermis). The simplified structure of human skin is 
portrayed in Figure 2.3. 
 
Figure 2.3 A schematic drawing of human skin structure (Murthy and 
Shivakumar, 2010). Three macroroutes for penetration through skin are 
labeled: Route 1—via hair follicles with associated sebaceous glands; Route 
2—via transepidermal (stratum corneum); Route 3—via sweat ducts. 
 
The stratified, avascular outer cellular epidermis can be divided into 
stratum corneum (horny layer), stratum lucidum (clear layer), stratum 
granulosum (granular layer), stratum spinosum (spinous or prickle layer) and 
stratum basale (basal layer; stratum germinativum) from topmost to 
bottommost (Monteiro-riviere and Riviere, 1999). 
The stratum corneum is the outmost layer of the epidermis composed of 
completely keratinized dead cells measuring 20-40 µm in diameter. The 
thickness of this layer varies by area of the body and between individuals. The 
cells in this layer are highly organized. Vertical interlocking columns (bricks) 
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are formed by cells stacking on one another. These “bricks” are interspersed 
with crystalline lamellar lipid matrix (mortar). The relatively polar lipids have 
a critical role in maintaining the barrier integrity of the stratum corneum 
(Murthy and Shivakumar, 2010). This ‘bricks and mortar’ arrangement 
(Figure 2.4) helps maintain the barrier function of the skin between human 
body and external environment. 
 
Figure 2.4 A schematic diagram of the “bricks and mortar” arrangement of 
human stratum corneum (Elias, 1991; Nemes and Steinert, 1999). 
Dark orange colored “bricks” are keratinocytes well-ordered. The bricks 
are surrounded by gray colored intercellular lipids (mortar). Bricks are linked 
by corneodesmosomes. There are 15 layers of brick rows with a total stratum 
corneum thickness of 13.1 μm. Representative dimensions are shown in the 
diagram. The keratinocyte diameter (d) is of 40 μm; the thickness of 
keratinocyte (t) is 0.8 μm; the vertical gap between keratinocytes (g) and the 
lateral spacing between keratinocytes (s) are the same, 75 nm. 
Mechanism of diffusion in stratum corneum. Route A represents the 
intercellular pathway and Route B represents the transceullar pathway. 
 
The stratum lucidum is a thin, translucent, homogenous layer containing 
fully keratinized, closely compacted, dense acaryote cells and cytoplasmic 
organelles. The stratum granulosum contains irregularly shaped, 
nonmembrane-bound, electron-dense keratohyalin granules that are known to 
have specific role in keratinization and barrier function. The stratum spinosum 
consists of several layers of irregular polyhedral cells. The keratinocytes in 
this layer have limited capacity for cell division. The stratum basale is a single 
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layer of columnar or cuboidal cells that keep epidermis replenished. The 
stratum corneum cells are constantly being sloughed from the epidermis 
surface. 
The dermis is filled with scattered fibroblasts, leukocytes, macrophages, 
mast cells, sweat glands, hair follicles and sebaceous glands. Blood vessels, 
lymphatic vessels, and nerve endings are embedded in this layer. The 
subcutaneous fat layer is the deepest layer of the skin connecting the dermis to 
the underlying skeletal components. It is about several millimeters thick 
consisting of the subcutaneous tissue. 
In transdermal delivery, the delivery system will face barriers built by the 
epidermis: the physical barrier mainly by stratum corneum; 
chemical/biochemical barrier including lipids, acids, hydrolytic enzymes, 
antimicrobial peptides and macrophages; and adaptive immunological barrier 
using humoral and cellular constituents of the immune system (Prausnitz and 
Langer, 2008). 
The stratum corneum provides the most efficient barrier to prevent the 
penetration of external substances through the skin due to its unique 
composition. The stratum corneum has a composition of 75-80% proteins (α–
keratin 70%, β–keratin 10%, proteinaceous cell envelop 5%, enzymes 10%), 
5-15% lipids (ceramides, fatty acids, cholesterol, cholesterol sulfate and 
sterol/wax ester) and 5-10% unidentified on a dry weight basis (Wilkes et al., 
1973). The protenaceous cell envelope is highly insoluble and resistant to 
chemical attack. The dermis also provides a barrier to the delivery of most 
polar drugs, though only to a minimal degree. The dermis poses a significant 
barrier to highly lipophilic molecules. 
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Therefore, the skin barrier, more specifically the stratum corneum, is a 
major challenge for delivery of bioactive ingredients and limits the efficacy of 
topically applied products. 
2.2.2.2 Routes of penetration through the skin 
There are three potential routes for molecules to cross the skin and reach 
the viable tissue (Figure 2.3): through hair follicles with associated sebaceous 
glands, across the stratum corneum, or via sweat pores (Barry, 2001a, 2002). 
Lipophilic molecules are enabled to cross the stratum corneum to the lower 
skin layer by passive diffusion due to permeation selectivity of stratum 
corneum. There are two pathways to cross the stratum corneum (Figure 2.4): 
intercellular and transcellular. 
Studies have revealed that the intercellular route is the major route of 
permeation in percutaneous absorption (Kligman, 1983; Lane et al., 2012). 
This indicates that the path length of effective tortuous intercellular diffusion 
channel for a permeant would be estimated around 500 μm, much longer than 
the thickness of the stratum corneum, based on the ‘brick and mortar’ model 
suggested by Elias (1983) (Figure 2.4). Intercellular spaces contain a complex 
mixture of structured lipids. This tortuous path greatly reduces the rate of 
penetration. 
For the transcellular route, it is the shortest distance. However, a diffusing 
molecule has to pass through a number of interfaces, lipophilic and 
hydrophilic domains. This series of interfaces repeat many times before the 
diffusant finally reaches the junction between the non-viable stratum corneum 
and the viable epidermis. 
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Appendageal route is a delivery route where the diffusing molecule 
reaches the subcutaneous tissue through the hair follicles with their associated 
sebaceous glands. The hair follicles are the most important appendages of 
human skin. They are embedded in the dermis, or even deeper into 
hypodermis. The hair follicles consist of internal root sheath, external root 
sheath, dermal papilla and hair matrix (Monteiro-Riviere, 2006).  
2.2.2.3 State-of-the-art of transdermal delivery systems 
There are three generations of development for transdermal delivery 
systems (Prausnitz et al., 2004). 
First-generation transdermal delivery systems are the most conventional 
one to deliver small, hydrophobic and low-dose drugs (e.g. transdermal 
patches). This generation has little or no enhancement at therapeutic rates for 
drugs that cross the skin. This approach is limited primarily by the stratum 
corneum. 
Second-generation transdermal delivery systems encompass chemical 
enhancers, iontophoresis and non-cavitational ultrasound (Karande et al., 2005; 
Karande et al., 2004). These methods enhance the penetration by disrupting 
the stratum corneum structure. The concentration gradient generated by these 
methods, adds driving forces for transdermal transport of small-molecule 
drugs. The major challenge for this generation is the balance between attaining 
increased percutaneous absorption and protecting deeper tissues from damage. 
Third-generation delivery systems utilize cavitation ultrasound, 
microneedles, thermal ablation, microdermbrasion, and electroporation (Denet 
et al., 2004; Pliquett and Weaver, 2007; Prausnitz, 2004). In particular, this 
 28 
 
generation enables transdermal delivery of macromolecules, including DNA, 
proteins, and virus-based vaccines. 
2.2.3 Advantages and formulation challenges of transdermal delivery 
Transdermal delivery is poised to be an attractive alternative to oral 
delivery and hypodermic injections thanks to a variety of advantages 
compared with oral and intravenous routes (Prausnitz and Langer, 2008). With 
regard to patients, transdermal delivery helps to avoid gastro-intestinal distress 
caused by ingesting and save those who have difficulty in swallowing or feel 
discomfort of injections. The transdermal route completely avoids the first-
pass effect of the liver that can prematurely metabolize drugs. It is non-
invasive, convenient and easy to administer and exhibits improved patient 
compliance. It only causes little or no discomfort and leaves no permanent 
sequelae such as scars. Whereas hypodermic injections are painful, 
inconvenient and generate dangerous medical waste and potential risk of 
disease transmission by needle re-use (Miller and Pisani, 1999). Transdermal 
delivery systems are generally inexpensive and can be self-administered. They 
can offer a steady level of drug in the system and provide long term release up 
to one week. 
The greatest challenge to deliver bioactive ingredients via the transdermal 
route is to penetrate the stratum corneum. Penetration of active substance 
across the skin, particularly, the stratum corneum is generally poor because the 
lipid matrix of the stratum corneum creates a formidable barrier to water, 
hydrophilic compounds and microorganisms (Donnelly et al., 2012). Only a 
limited number of drugs with a few hundred Dalton molecular mass and high 
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octanol-water partition coefficient (logP) values, are amenable to be 
administered by this route (Gad, 2009). 
Transfollicular is one of the transdermal delivery routes. Effectiveness of 
transfollicular penetration depends on the state of the hair follicle, i.e. open or 
closed. However, transfollicular delivery has not been regarded as a significant 
route for delivery due to the limit amount of hair follicles in the skin surface 
(less than 0.1%) (Barry, 2002; Bouwstra, 1997). 
Via stratum corneum is the most important delivery route for topical 
application. There has been extensive research on strategies to enhance 
delivery of active ingredients focusing on penetration through the stratum 
corneum. Both chemical and physical methods have been introduced 
(Prausnitz and Langer, 2008). 
Chemical enhancers for skin penetration are functionalized by disrupting 
the lipid bilayer structures of the stratum corneum thus providing easier 
passage of active substances (Karande et al., 2005; Williams and Barry, 2004). 
The more effective chemical enhancers are more prone to be toxic and cause 
skin irritation. Incorporation with oil may improve skin permeation, and it is 
likely required for the penetration enhancement. However, high levels of oil 
will impart aesthetic negatives that raise consumer compliance challenge. 
Thus, anesthetically elegant and non-greasy formulation is required. 
Physical methods such as iontophoresis, sonophoresis and thermal 
poration, disturb the microstructure of the stratum corneum and create 
transient microscopic aqueous channels that entitle increased skin penetration 
of active substances (Park et al., 2008). Nevertheless, there are concerns that 
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physical methods are possible to introduce excessive damage, burning and 
irritation. 
Nanoparticles are promoted as a strategy to overcome the skin barrier 
(Baroli, 2010; Jain et al., 2003; Touitou et al., 2000). Though the small size 
particles may be a hazard to health, the toxicity is determined by chemistry 
more than size. Liposome is a widely used approach to enhance penetration by 
carrying hydrophilic contents through the lipid bilayer barrier as intact vesicles. 
However, the effectiveness of liposomes as penetration enhancers is under 
debate. 
 
2.3 Nanoemulsion as Delivery System 
Appropriate delivery systems are formulated to facilitate administration of 
the active substance by selected route. The type of delivery system limits the 
route of administration, and vice versa. The active substance can be 
formulated into several delivery systems having selected characteristics 
suitable for specific application. Characteristics of the delivery system 
influence the delivery of active substance, tolerability and consumer 
preference. For cosmeceutical formulations, the psychological impact of the 
appearance of the final product (cosmeceutical vehicle) on the consumer is a 
unique feature to be measured in addition to the performance. A preference for 
transparent emulsions, ‘oil-free’ products, or the use of natural compounds has 
been observed in the market (DiSapio, 1993; Nohynek et al., 2010). Hence, 
proper balancing of active cosmeceutical ingredient efficacy and delivery 
system properties is critical to develop cosmetically appealing formulations. 
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There are various delivery systems regarding topical delivery that can be 
generally classified as liquids, semisolids and solids. The most popular 
approach is the incorporation of the active substance into inert lipid vehicles 
such as oils, surfactant dispersions, liposomes, microemulsions, and 
nanoemulsions. The nanoemulsion technique is one of the most promising 
methods to enhance transdermal permeation and percutaneous absorption of 
an active substance. The study of nanoemulsions has become a rapidly 
growing research field in formulation community and the development of oil-
in-water nanoemulsion has attracted an immense amount of interest owing to 
their outstanding properties. 
2.3.1 Definition and characteristics of nanoemulsion 
Terminology. A nanoemulsion is a true emulsion with droplets of 20-
200 nm in diameter (Mason et al., 2006; McClements and Rao, 2011; 
Sonneville-Aubrun et al., 2004). The emulsion droplet is the dispersed phase. 
The continuous phase makes up the surrounding liquid. Resembling a 
conventional emulsion, a nanoemulsion consists of two immiscible liquid 
phases, one is hydrophobic and the other is hydrophilic. Nanoemulsion is also 
known as mini-emulsion (Asua, 1997). 
A nanoemulsion can be categorized into oil-in-water (o/w) nanoemulsion 
and water-in-oil (w/o) nanoemulsion, depending on the distribution of oil and 
aqueous phases. An oil-in-water nanoemulsion refers to a system having oil 
droplets dispersed in an aqueous phase. It is a favorable delivery system for 
hydrophobic active substances whereas a water-in-oil nanoemulsion is suitable 




Small droplet size and narrow size distribution. The droplet size in a 
nanoemulsion is one of the most important characteristics. It influences optical, 
rheological, stability, and release characteristics. The small droplet size also 
has a potential to alter the biological fate of the delivery system (McClements 
and Rao, 2011). The small droplet size and narrow size distribution imparts a 
number of overwhelming advantages to a nanoemulsion over other delivery 
systems. The droplet size is so small that it only scatters light weakly. This 
characterizes the appearance of nanoemulsions, optically clear or slightly 
turbid. Moreover, the small droplet size and narrow size distribution contribute 
to a high kinetic stability of nanoemulsion against aggregation and 
gravitational separation by Brownian motion. 
Low concentration of surfactant.  Both microemulsion and 
nanoemulsion systems require surface-active molecules to stabilize the 
interface of two immiscible phases. Surfactants serve as emulsifiers that 
adsorb to the surface and the interface, preventing the aggregation of droplets. 
Microemulsion was introduced as early as the 1940s and they are of interest as 
a drug delivery system due to its simplicity of manufacture, thermodynamic 
stability and high solubilization capacity (Fanun, 2012). Microemulsion is 
defined as a system of water, oil and amphiphile which is a single optically 
isotropic and thermodynamically stable liquid solution (Danielsson and 
Lindman, 1981). It shares the similar system classification as nanoemulsion. 
Surfactant is the critical component in microemulsion formation and the large 
amount of surfactant required to produce microemulsion is a major concerns 
of the microemulsion due to surfactant-induced toxicity and side effect, 
consumer compliance and excipients acceptability (Lawrence and Rees, 2000). 
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Nevertheless, it is possible to fabricate a nanoemulsion with much less 
surfactant (~3-10 wt%) than a microemulsion (>20 wt%) (Tadros et al., 2004; 
Tamilvanan, 2008). 
Enhanced solubility and absorption of active ingredient.
 Nanoemulsions can encapsulate active ingredients inside the dispersed 
phase so as to increase their bioavailability and efficacy due to an increased 
surface area resulting from a decrease in droplet size (Gao et al., 2008).As a 
result of enhanced bioavailability and efficacy of cosmeceuticals, there can 
also be a reduction in toxicity and in the amount required to fulfill biological 
benefits. Moreover, incorporation of an active ingredient into a nanoemulsion 
offers protection against chemical degradation, as well as allowing either 
immediate or sustained release, depending on the polymorphic transitions of 
the lipid matrix. 
Thermodynamically unfavorable system. Nanoemulsions are 
thermodynamically unstable system because the free energy of the separated 
two phases (oil phase and water phase) is lower than that of the one-phase 
emulsion itself. Consequently, nanoemulsions will always tend to breakdown 
over time due to various physicochemical phenomena namely gravitational 
separation, coalescence, flocculation, and particularly Ostwald ripening 
(Müller-Goymann, 2004; Tadros et al., 2004). Therefore, the major concern of 
a nanoemulsion formulation is to create sufficiently small droplets in order to 
ensure that the system has a satisfactorily long kinetic stability for commercial 
applications. The long term physical stability of a nanoemulsion can be 
achieved by means of electrostatic or steric stabilization, static by solid 
particles at the interface, or increasing the viscosity of the system. Thus 
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nanoemulsion, sometimes, can be labeled as “Approaching Thermodynamic 
Stability” (Tadros et al., 2004). 
2.3.2 Composition and formation of nanoemulsion 
In this section, the major components to formulate a nanoemulsion are 
introduced. The emulsifier system and the oil phase are the most important 
factors in developing a nanoemulsion. These components impact on the 
formulation method and properties of the end product (Azeem et al., 2009b; 
Sarker, 2005). 
Formation of a nanoemulsion can be divided into two approaches, a high-
energy approach and a low-energy approach depending on the underlying 
principle (Anton et al., 2008; Solans et al., 2005). The high-energy approach 
involves the use of specific devices to produce mechanical energy. The low-
energy approach depends on the intrinsic physicochemical properties of the 
formulation materials, in particular, the surfactants, leading to the formation of 
nano-sized emulsion droplets. 
2.3.2.1 Components of nanoemulsion 
Surfactant. Surfactant is a critical component of nanoemulsion 
system. Surfactant is an amphiphilic molecule consisting of a non-polar 
hydrophobic “tail” group and a polar hydrophilic “head” group. It is a surface 
active molecule that locates at the interface of two immiscible phases, i.e. oil-
water interface, air-water interface. It is utilized to stabilize the internal phase 
in the emulsion. Surfactants contribute to the total quantities of solubilized 
active ingredient and the amount of oil stabilized in the system. There are 
three major categories of surfactant namely ionic surfactant, non-ionic 
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surfactant and zwitterionic surfactant (Tadros, 2005b). Ionic surfactants are 
negatively or positively charged and are limited in use because of their 
tendency to cause irritation. Zwitterionic surfactants have both anionic and 
cationic groups on the same molecule. It has been reported that a zwitterionic 
surfactant alone cannot form or stabilize nanoemulsions efficiently. Non-ionic 
surfactants have been widely used in nanoemulsion formulations owing to 
their low toxicity and low tendency to cause irritation, and a good capacity to 
formulate nanoemulsions through both high-energy and low-energy 
approaches (McClements and Rao, 2011). 
The concentration of surfactant used to fabricate a nanoemulsion affects 
not only the amount of oil that can be incorporated into the formulation, but 
also the droplet size of nanoemulsion. Typically, an increase in surfactant 
concentration will lead to a higher concentration of oil to be solubilized in the 
system and/or a decrease in droplet size. 
Cosurfactant. Cosurfactants used in nanoemulsion formulation are 
amphiphilic molecules as well. Although cosurfactants are usually not good at 
emulsification, they can improve the efficiency of formation and stability of 
nanoemulsion formulations when used with the surfactant. The role of a 
cosurfactant in nanoemulsion formation is 1) to fluidize the interface, 
providing flexibility of the interface between oil and aqueous phase and 
introducing appropriate interfacial curvature, 2) to enhance the capacity of 
surfactant to solubilize active ingredient, 3) to increase the hydrophilic 
surfactant solubility in the oil phase, 4) to optimize the viscosity ratio of 
disperse-to-continuous phase. The main issue to be considered for using a 
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particular cosurfactant is compatibility, because cosurfactant can alter the 
structure and interaction of the molecules in the aqueous phase. 
Oil. Oils used to make up the oil phase in nanoemulsions are non-
polar components, such as triacylglycerols, diacylgycerols, monoacylglycerols, 
fatty acids, essential oils, flavor oils, mineral oils and so on (Mason et al., 
2006; McClements and Rao, 2011). The physicochemical characteristics of the 
oil phase such as phase behavior, polarity and water solubility, viscosity, 
refractive index, density etc, greatly affect the formation, stability and 
properties of a nanoemulsion. The properties of the oil phase in a 
nanoemulsion formulation have direct influence on 1) toxicity and 
biocompatibility, 2) loading capacity and stability of active ingredient in the 
system, 3) efficiency of nanoemulsion formation, 4) release control of the 
active ingredient from the matrix, 5) stability of the end product. 
Others. There are many other ingredients that can be incorporated into 
a nanoemulsion formulation. Texture modifiers can be added to the 
formulation to thicken or gel the aqueous phase. Weighting agents are often 
incorporated into the oil phase to match their density to that of the surrounding 
aqueous phase. Ripening retarders are used to stabilize oils which are 
susceptible to Ostwald ripening. 
2.3.2.2 High energy approaches 
Formation of a nanoemulsion by high-energy emulsification methods is 
generally accomplished using high-shear stirring, high-pressure homogenizers 
and ultrasound generators. A high-pressure homogenizer is the most widely 
used emulsifying machine to prepare nanoemulsions because it takes the 
shortest time, produces the most homogeneous material and produces the 
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smallest droplet size (Innings et al., 2011; Perrier-Cornet et al., 2005). 
Ultrasonic emulsification is only appropriate for small batches (Solans et al., 
2005). 
High-pressure homogenizer. A high-pressure homogenizer provides 
intense disruptive forces. When the larger droplets in the preliminary prepared 
coarse emulsion pass through the valve, they are broken down into smaller 
ones (Figure 2.5). The homogenizing pressure, number of passes, dispersed to 
continuous phase viscosity ratio, and amount of emulsifier contribute to the 
droplet size obtained by this method (Floury et al., 2000; Håkansson et al., 
2009; Mohr, 1987). In practice, extremely high operating pressure and 
multiple passes through the homogenizer are necessary to reduce the droplet 
size, achieving the level required in nanoemulsion. High emulsifier levels, low 
interfacial tensions, and appropriate viscosity ratios lead to a droplet size less 
than 100 nm in radius (Floury et al., 2000). 
The homogenization process can be divided into three stages: 
fragmentation, coalescence and adsorption (Håkansson et al., 2009). 
Homogenization pressure (the amount of dissipated energy) and viscosity of 
the dispersed phase (drop deformation time relative to the turbulent eddy life 
time) are two important parameters for fragmentation affecting the 
homogenization result (Tjaberinga et al., 1993; Walstra and Smulders, 1998). 
Turbulent dominant fragmentation is generally considered as the first order 
process followed by coalescence as a second order process. Reduction of 
surface tension, alternation of the rigidity of the surface and stabilization of 
Laplace pressure increase fragmentation (Jones and Middelberg, 2003). 
Emulsifiers hinder the coalescence by adsorbing at the interface owing to 
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repulsive forces and dynamic adsorption processes (Narsimhan and Goel, 
2001; Walstra, 1993). Turbulent and Brownian (diffusion) motion results in 
movement of particles, collision and adsorption. 
 
Figure 2.5 Schematic representation of high pressure homogenization 
method. 
Microfluidizer. A microfluidizer is similar to a high pressure 
homogenizer in design except for the channels. The emulsion flowing through 
the channels is divided into two streams. Each stream passes through a 
separate fine channel and they impinge upon each other in the interaction 
chamber, leading to highly efficient droplet disruption. Similar to a high 
pressure homogenizer, the droplet size produced tends to decrease with 
increasing homogenizing pressure, number of passes, and emulsifier 
concentration. In addition, the viscosity ratio of disperse-to-continuous phase 
should be within a certain range to facilitate the formation of small droplets 
(Jafari et al., 2006, 2007). 
Ultrasonic homogenizer.   An ultrasonic homogenizer utilizes high 
intensity ultrasonic waves to create intense disruptive forces that break up the 
dispersed phases into very small droplets. It is important to ensure that the 
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emulsion spends sufficient time within the region where droplet disruption 
occurs for efficient and uniform homogenization (McClements, 2012). The 
intensity of the ultrasonic waves, residence time, type and amount of 
emulsifier present and the viscosity of the oil and aqueous phase all affect the 
homogenization efficiency (Canselier et al., 2002; Leong et al., 2009). 
2.3.2.3 Low energy approaches 
A nanoemulsion can be almost spontaneously prepared by altering the 
composition of the formulation or the environment without significant energy 
input (Calderó et al., 2011; Forgiarini et al., 2001; Wang et al., 2008b). 
Though low energy methods are effective at producing nanoemulsions of 
small droplet size, they are limited in the type of oil phase and emulsifier that 
can be used. Spontaneous emulsification and phase inversion methods are the 
two main low-energy approaches to nanoemulsion formation. 
Spontaneous emulsification. Spontaneous emulsification is carried out 
very simply: the emulsion is created as a result of mixing of two liquids at 
room temperature, a pure aqueous phase and a mixture of oil, surfactant and 
cosolvent (Anton and Vandamme, 2009). The mechanism of spontaneous 
emulsification is the displacement of hydrophilic material caused by varying 
the compositions of the two phases, the environmental conditions or the 
mixing conditions. The nanoemulsion properties such as droplet size and size 
distribution are closely linked to composition. 
Phase Inversion Temperature (PIT) method. The PIT method is the 
most popular low-energy method in industry. Oil, nonionic surfactant and 
water are mixed together at room temperature and slightly stirred. When 
heated, the solubility of surfactant progressively changes from hydrophilic to 
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lipophilic, where an emulsion is transformed from one type to another (i.e. w/o 
to o/w or o/w to w/o) (Anton and Vandamme, 2009; McClements and Rao, 
2011). The nanoemulsion is spontaneously formed by varying the 
temperature-time profile of the mixture. The PIT should be determined 
beforehand. 
2.3.3 Advantages and formulation challenges of nanoemulsion 
The attractions of nanoemulsions for application in personal care and 
health products are due to the following advantages: 
The transparent appearance of nanoemulsion and its fluidity at a 
preferable oil concentration give the nanoemulsion product a pleasant 
aesthetic character and skin feel. The small droplet size of nanoemulsion 
prevents flocculation, coalescence, and gravity-induced sedimentation or 
creaming, phase separation and surface fluctuation during storage. Wetting, 
spreading and penetration can be enhanced due to the low surface tension of 
the whole system and low interfacial tension of the o/w phases (Tadros, 
2005a).  
Nanoemulsion can enhance the skin permeation due to following reasons. 
With the increase in active ingredient solubility in the nanoemulsion, the 
greater concentration gradient facilitates the passive diffusion. When across 
the stratum corneum, oil droplet not only carries the active ingredient directly 
entering the stratum corneum without fusion on the skin surface, but also 
provides a liquid pool within the bilayer by perturbing the stratum corneum 
and creating separate domains, thus induces highly permeable pathways in the 
stratum corneum. Formulation components such as surfactant and cosurfactant 
can act as permeation enhancers. When across the skin through hair follicles 
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and via sweat pores, the small droplet size (less than 40 nm) of nanoemulsion 
can be efficiently penetrated through (Vogt et al., 2006). 
The reduced amount of surfactant in nanoemulsion formulation 
significantly reduces surfactant-induced skin irritation. Nanoemulsions can be 
designed to form gel systems at much lower droplet concentration than 
conventional emulsions (McClements and Rao, 2011). 
Two major concerns in formulation considerations are efficiency of 
nanoemulsion formation and stability of a nanoemulsion (Capek, 2004). Oil 
used to make up the oil phase in a nanoemulsion system not only influences 
the nanoemulsion formation but also affects end-product stability. Though it is 
desirable to use triacylglycerol oils because of their low cost, abundance and 
functional attributes, their use in nanoemulsion formulation is limited because 
of following reasons: their high viscosity limits droplet disruption within a 
high pressure homogenizer; high level of hydrophobicity makes it difficult to 
prepare nanoemulsions by PIT method; high interfacial tension with the 
aqueous phase challenges the emulsifiers to stabilize the interface. In contrast, 
when using oils of low viscosity, relatively high polarity, and low interfacial 
tension to formulate nanoemulsion, it is very likely that the nanoemulsion 
formed will easily breakdown because of Ostwald ripening or coalescence. 
The relatively high water-solubility of oil causes diffusion of oil molecules 
from small to large droplets, which leads to droplets growing. The low 
interfacial tension makes oil droplets more prone to coalescence. 
Regarding to the reduced amount of emulsifiers, efficiency of surfactant 
or combined with cosurfactant on facilitating nanoemulsion fabrication is of 
importance when selecting emulsifier system (Azeem et al., 2009a; Donsì et 
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al., 2012). Emulsifier system should effectively stabilize the o/w interface. 
During high energy homogenization process, it is important to ensure that 
sufficient emulsifier rapidly adsorbs to newly formed droplet surface and 
covers it well to prevent re-coalescence. 
With respect to the active ingredient in a formulation, the primary goal of 
nanoemulsion as a carrier system is to protect and deliver the active ingredient 
incorporated inside. Hence, compatibility of formulation ingredients with the 
active ingredient and capacity of formulation ingredients to solubilize and 
stabilize the active ingredient should be considered. Prerequisite information 
such as physicochemical properties of the active ingredient is needed to select 
proper emulsifier system and oil phase. 
2.3.4 Practical application of nanoemulsion 
Nanoemulsions have been developed for medical applications in the 
pharmaceutical field as drug delivery systems (Mei et al., 2013; Sarker, 2005). 
Both hydrophobic and hydrophilic drug molecules can be incorporated into the 
droplets of o/w or w/o nanoemulsion for potential pharmaceutical uses. 
Nanoemulsions can be applied through oral, parenteral, ocular, nasal and 
topical routes for medical applications (Tamilvanan, 2008). 
In personal care and well-being industries, nanoemulsions may provide 
interesting alternatives due to some features that they are pleasantly 
transparent and have various rheological properties. A great variety of 
products with different visual aspects, richness and skin feel are fulfilled by 
nanoemulsions: lotions, transparent milks, crystal-clear gels with different 
rheological behavior (Sonneville-Aubrun et al., 2004). While being appealing 
from an optical and rheological point of view, nanoemulsions also can deliver 
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moisturizers to the skin quite efficiently and block ultraviolet light without 
leaving a white residue. The small size of the droplets will likely increase 
transport efficiency of the active substance or other molecules inside the 
droplet across biological membranes, including the skin. Since a 
nanoemulsion offers simple way to deliver an internal phase active ingredient 
whilst retaining the feel of the external phase, it shows great potential from a 
cosmetic point of view (Brandt et al., 2011; Morganti et al., 2001). 
Nanoemulsion products are easily valued in skincare products by good 
biophysical and sensorial benefits. Type of emulsion (o/w or w/o) and 
rheological properties (lotion or cream) depend on the final requirements for 
the product (moisturizing cream, nourishing cream, massage cream) and the 
skin conditions of user (dry or oily skin). 
Nanoemulsions have also received great attention in nutrition and food 
science. The market is encouraging the application of nanoemulsions in food 
and beverage industries due to its ability to encapsulate functional components 
such as flavors, antioxidants and nutraceuticals (McClements, 2011; Velikov 




CHAPTER 3 METHODOLOGY 
 
3.1 Materials 
The cosmeceutical material, schizandrol A was purchased from Chengdu 
Biopurify Phytochemicals Ltd. (Sichuan, China). Ethanol was obtained from 
Merck. Propylene glycol (PG), poly(ethylene glycol) (PEG 200, 400, 1000, 
4000, 6000 and 8000) and glycerin (GL) were purchased from Sigma-Aldrich. 
Sucrose laurate (L1695) was obtained from Mitsubishi-Kagaku Foods 
Corporation. Polyoxyethylene (20) sorbitan monolaurate (Tween 20), 
polyoxyethylene (20) sorbitan monopalmitate (Tween 40), polyoxyethylene 
(20) sorbitan monooleate (Tween 80), β-cyclodextrin (β-CD), γ-cyclodextrin 
(γ-CD), 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), and 2-hydroxypropyl-γ-
cyclodextrin (HP-γ-CD) were obtained from Sigma-Aldrich. Oils such as 
ethyl-n-butanoate, triacetin (TA), ethyl-n-octanoate, oleic acid (OA), ethyl 
oleate (EO), isopropyl myristate (IPM), isopropyl palmitate (IPP), and castor 
oil (CO) were purchased from Sigma-Aldrich. 
All other chemicals for HPLC assay were of HPLC grade supplied by J.T. 
Baker. All chemicals were used as received without further purification. Ultra-
pure water (Millipore-Q® Gradient A10™ ultra-pure water system, Millipore, 




3.2 Experimental Design 
 




Preformulation characterization. The first stage comprises 
fundamental studies known as preformulation. It involves an understanding of 
physicochemical properties of schizandrol A and other formulation component 
candidates, and how they interact in the proposed delivery system. It is vital to 
understand the chemical entity and functional groups of the proposed active 
substance. Identification of the active cosmeceutical ingredient, schizandrol A, 
should be confirmed to avoid misapplication. It is necessary to investigate 
physicochemical properties of schizandrol A at an early stage of development 
to assist selection of suitable formulation components. 
Next, is the selection of suitable components for the delivery system 
based on their capacity to improve the solubility of schizandrol A. Efficacy of 
solubility enhancement strategies, including micellization, cosolvency, 
complexation and their combinations, was evaluated. Solubility of schizandrol 
A in mixtures of different kinds of solubilizing agents was studied to 
understand the interaction between solubilizing candidates and their 
compatibility. Finally, schizandrol A solubility in different oils was studied to 
determine a suitable oil phase for nanoemulsion. Pseudo-ternary phase 
diagrams were constructed to optimize weight ratio of surfactant to 
cosurfactant (Sm) and to indicate compatibility of oil with emulsifier system. 
Formulation development. There are two most important aspects at 
this stage, process parameters and formulation variables, to optimize 
nanoemulsion formation. The process of high pressure homogenization 
depends on type and amount of oil and emulsifiers, surfactant to cosurfactant 
weight ratio, operating pressure, and number of passes. Mean droplet size and 
polydispersity index were utilized to evaluate their performance. The efficient 
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number of passes indicates that the opaque coarse emulsion sample will 
become be optically clear after this number of passes. The efficient number of 
passes gives information on the feasibility of the high pressure 
homogenization method. 
Characterization of nanoemulsion containing schizandrol A. Based on 
the results from the studies of process parameters and formulation variables, 
nanoemulsion formulation was optimized using three kinds of emulsifier 
compositions to investigate schizandrol A loaded nanoemulsion formulation. 
The resultant nanoemulsion containing schizandrol A was subject to a series 
of physicochemical characterizations to establish quality and performance 
profiles. The physical stability of nanoemulsions against temperature change 
and over storage time was evaluated using droplet size measurement. The 
chemical stability was evaluated by the schizandrol A concentration in the 
formulation over store time. Centrifugation is a wide-use method to determine 
the coalescence pressure of emulsions (André et al., 2003). A gravitational 
field as high as 6708xg was applied to indicate the stability of the proposed 
nanoemulsion formulations against creaming and sedimentation. Heating and 
cooling processes were used to test the potential of the formulation 
degradation after repeated heating/cooling cycles. Freeze-thaw cycles may 
induce destabilization of the formulation due to crystallization of oil droplets 
during freezing and coalescence when melting (Cramp et al., 2004). 
To study transdermal absorption of schizandrol A, a Franz diffusion cell 
was used with a commercially available synthetic membrane minimizing the 
variability associated with animal or human skin. A soaking procedure was 
conducted to maintain uniformity in membrane preparation. The use of Franz 
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diffusion cell to assess skin permeability provides insights into relationships 
between the skin, active substance and formulation. 
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Table 3.1 Factors and levels of experiments. 
Experiment Factor Level Remark 
Phase solubility 
studies 
Solubilizing agent type 3 Surfactant, cosolvent, complexant 
Concentration 3 1, 5, 10 wt% 
Combination 3 
Mixed micelle, surfactant/cosolvent, 
surfactant/complexant 
Phase diagram 
Cosurfactant type 3 Ethanol, propylene glycol, PEG 400 





Pressure (MPa) 3 100, 150, 200 
Homogenization passes 5 10, 20, 30, 40, 50 
Formulation 
variable 
Oil concentration 3 10, 15, 20 wt% 
Emulsifier concentration 3 3, 5, 7 wt% 
Cosurfactant type 3 Ethanol, propylene glycol, PEG 400 




Cosurfactant type 3 Ethanol, propylene glycol, PEG 400 





3.3.1 Preformulation characterization 
3.3.1.1 Elemental analysis 





were carried out at room temperature on a Bruker Ultra-shield Avance-400 
spectrometer (Larmor frequencies ν0 (
1
H)=400.23 MHz, ν0 (
13
C)=100.65 MHz) 
using a Bruker BBO probe. Schizandrol A was dissolved in deuterated 
chloroform (CDCl3) in a 5 mm NMR tube (NE-HL5-7) sealed with a green 
polyethylene cap and parafilm. A zg 30 pulse program was used for 
1
H-NMR 
covering a sweep width of 11990.407 Hz giving an acquisition time of 2.70 
seconds and 1 second relaxation delay. A total of 64 scans were collected into 
63.23 K time domain data points. 
For 
13
C-NMR analysis, a zgpg 30 pulse program was applied and 512 
scans were recorded with acquisition parameters as follows: sweep width of 
25125.629 Hz, acquisition time of 1.30 seconds, a relaxation delay of 2 
seconds and 64 K time domain data points. 
All chemical shifts (δ) were reported in ppm referenced to TMS 
(tetramethylsilane, (CH3)4Si) which is used as an internal standard. The 
regions corresponding to deuterated chloroform were excluded. 
3.3.1.2 Phase analysis 
Powder X-ray diffraction (PXRD). PXRD measurement was 
performed on a Bruker D8-ADVANCE X-ray diffractometer (Bruker, 
Germany) using CuKα radiation at wavelength 1.54 Ǻ as X-ray source at room 
temperature controlled by Diffrac plus XRD commander software. The 
voltage and current applied were 35 kV and 40 mA, respectively. Samples of 
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schizandrol A were spread on PMMA specimen holder rings obtaining a 
smooth flat surface and scanned from 5° to 50° (2θ) with a step size of 0.008 
and 0.1 sec/step. The divergence and anti-scattering slits were set to 0.3°. Data 
analysis was performed using ‘EVA Part 11’ version 11.0.0.3. 
Fourier transform Infra-red (FTIR). FTIR spectrum of schizandrol A 
samples were recorded by Variance FX3000MX FTIR spectrometer (BIO-
RAD EXCAUBUR Series) from 400 to 4500 cm
-1
 spectral range with a 
resolution of 4 cm
-1
 and 16 scans. The samples were properly diluted and 
finely ground with potassium bromide (KBr) powder and pressed to obtain a 
suitable-size pellet for measurement. The absorption intensity of schizandrol A 
is in a relative scale with a background spectrum. 
3.3.1.3 Thermal analysis 
Thermogravimetric analyzer (TGA). TGA measurement was carried 
out using a Simultaneous DSC–TGA (STD2960, TA Instruments) to 
determine weight changes (wt %) as a function of temperature. The weight 
change of the schizandrol A sample was measured while the sample was 
heated at a constant heating rate 5 °C/min from 24.5 °C to 800 °C in a nitrogen 
atmosphere. 
Differential scanning calorimetry (DSC). DSC experiments were 
performed on a Pyris Diamond DSC Calorimeter (Perkin Elmer, USA). 
Schizandrol A sample was placed in a standard aluminum DSC pan and sealed 
lid containing pinholes. The sample was heated from 25 °C to 200 °C at a 




3.3.2 Phase solubility studies 
3.3.2.1 Schizandrol A solubility measurement 
In order to select the most suitable media for formulation containing 
schizandrol A, equilibrium solubility of schizandrol A samples was 
determined in different systems. Solubilizing agents mixed with ultrapure 
water at various concentrations were studied for non-ionic surfactants (Tween 
20, Tween 40, Tween 80, L1695), and cosolvents (ethanol, propylene glycol, 
glycerin, polyethylene glycols (PEG 200, 400, 1000, 4000, 6000 and 8000)), 
with a concentration ranging from 1, 5 to 10 wt%. This range was chosen 
because surfactant used for nanoemulsion usually will not exceed 10 wt% of 
the whole formulation. 
Cyclodextrins (HP-β-CD, γ-CD, HP-γ-CD) as complexants were studied 
in a concentration ranging from 5, 10, 20, 40 to 80 mM, and 5, 10 mM for β-
CD. The concentration at which β-CD can be studied is much lower than the 
other complexants due to its low aqueous solubility (18.5 gL
-1
, 25 °C) and its 
toxicity profile. 
Capacity of oils to solubilize schizandrol A was studied by directly 
dissolving schizandrol A in the pure oil phase. 
Excess schizandrol A was added to 5 ml of liquid media in a capped vial 
and stirred (~500 rpm) for 48 h at room temperature to reach equilibrium. The 
point at which the suspension became turbid was considered to be the 
maximum solubility. The resultant solutions were filtered through a 0.45 µm 
pore-size filter for HPLC analysis. 
High performance liquid chromatography (HPLC) assay of schizandrol A.
 An Agilent Series 1100 HPLC system with a reversed phase column 
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(Lichrosorb RP-18, Dimension 4.6x200 mm, 5 micron packing size, Agilent 
Technologies) was used to determine the concentration of schizandrol A. The 
HPLC system consists of a standard quaternary pump, a variable wavelength 
detector (VWD), an auto-sampler and a vacuum degasser (Model G1311A) 
controlled by Chemstation software. The mobile phase consisted of a mixture 
of methanol (75% v/v) and water (25% v/v) and was delivered at a flow-rate 
of 1 ml/min at 35 °C. The sample injection volume was 20 µl and schizandrol 
A was detected at 254 nm. Retention time was approximately 4 min. 
Calculation of schizandrol A concentration was done using a standard 
calibration curve in a range from 10-1000 µg/ml in methanol with a 
correlation coefficient of 0.999. 
3.3.2.2 Stability of schizandrol A in aqueous solutions 
Physical stability.    The droplet size change of selected micelle systems 
containing 1 mg/ml schizandrol A was analyzed from 20 ºC to 60 ºC by DLS. 
Effect of temperature and storage time.    Selected micelle systems 
containing 1 mg/ml schizandrol A were stabilized for 24 hours at room 
temperature under 500 rpm stirring and placed at 4 ºC, room temperature and 
50 ºC for storage. Schizandrol A concentration in each system was analyzed 
by HPLC to determine chemical stability of schizandrol A in the aqueous 
solutions. Samples kept under room temperature and 4 ºC were assessed at 
day’s interval up to 10 days, week’s interval up to 100 days. Samples stored at 
50 ºC were tested up to 30 days. 
Chemical stability under UV exposure.    Selected micelle systems 
containing 1 mg/ml schizandrol A were prepared and equilibrized for 24 hours 
under 500 rpm stirring at room temperature. Samples were then placed in the 
 54 
 
INTELLIRAY 400 UV flood light curing area (8X6 inch) for UVA radiation 
exposure with evenly distributed 100 mW∙cm-2 UVA light (λ=320–390 nm). 
Chemical stability of samples (determined by schizandrol A concentration 
using HPLC analysis) was assessed after 1, 2, 3, 4, 5, 6, 24 hours. 
3.3.3 Construction of pseudo-ternary phase diagram 
A water titration method was used to develop pseudo-ternary phase 
diagrams to investigate concentration ranges of components for monophasic 
region formation at room temperature. Sucrose laurate (L1695) was used as 
main surfactant, ethanol, propylene glycol and PEG 400 as cosurfactant 
respectively, ethyl butanoate served as oil phase based on solubility studies. 
Surfactant and cosurfactant (S/CoS) were mixed at different weight ratios 
of 1:2, 1:1 and 2:1. These ratios were chosen in increasing concentration of 
surfactant with respect to cosurfactant for a detailed phase study. 
For each phase diagram, a predetermined amount of oil, surfactant and 
cosurfactant were mixed thoroughly using a magnetic stirrer (~500 rpm) at 
room temperature to make weight ratios Ro=(ethyl butanoate)/(L1695+CoS) of 
1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1 separately. Different weight ratios 
cover the full range so as to delineate the boundaries of phases precisely in 
phase diagrams. 
These mixtures were continuously titrated with water. After each addition, 
system was examined for physical appearance by visual observation. Phase 
boundaries were determined by end point of titration where solution becomes 
turbid. The quantity of water required to make the mixture turbid was recorded. 
The physical state of emulsion was marked on a pseudo-three-component 
phase diagram, with one axis representing the water phase, the second one 
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representing a mixture of surfactant and cosurfactant at fixed weight ratio and 
the third representing the oil. 
3.3.4 Preparation of nanoemulsion 
A preliminary coarse emulsion was prepared. First, surfactant, 
cosurfactant and oil were mixed together by stirring using a magnetic stirrer at 
500 rpm at room temperature until a clear sample was obtained. Water was 
then slowly added into the system at room temperature. Samples were then 
pre-homogenized by a high shear mixer (IKA Dispersers, T10 Ultra-Turrax®) 
for 10 min (~15,000 rpm) at room temperature. An increase by ~4 ºC in pre-
homogenization temperature was observed at the end of mixing. Though at 
this initial stage use of a high shear mixer has no significant effect on the final 
droplet, it was used to improve mixing and size distribution. 
Coarse emulsions at an initial temperature (Tin) of 27±1 ºC were 
processed using a high pressure homogenizer (AVESTIN C5). The high 
pressure homogenizer used in the present work is of piston-gap type 
developed by Avestin™. It consists of a piston intensifier to generate high 
pressure, and a high pressure valve equipped with a specially designed seat. 
The coarse emulsion under pressure is forced through the high pressure 
valve gap which is a small orifice of micrometers width and is accelerated to 
very high velocity over a very short distance. The intense shear forces and 
extensional stress are thereby generated by the steep pressure gradient between 
the inlet and outlet of the high pressure valve. Mechanical forces such as 
laminar forces, turbulent force, and cavitation contribute to droplet disruption 
at the outlet of the valve gap. The outlet temperature is higher than the inlet 
temperature because of conversion of kinetic energy into heat. 
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In the present study, various homogenization processes were performed 
according to the experimental design. Processed emulsions were collected for 
physical appearance observation and droplet size analysis after every 10 
passes. 
3.3.5 Physicochemical characterization of nanoemulsion 
3.3.5.1 Optical measurement 
Physical appearance of the resultant samples after high pressure 
homogenization was observed by visual inspection. A clear solution without 
any crystal present was considered to be a successfully prepared nanoemulsion. 
3.3.5.2 Analysis of droplet size and polydispersity index 
Dynamic light scattering (DLS).  The DLS technique (also referred to 
photon correlation spectroscopy (PCS)) was employed to determine droplet 
size and polydispersity of nanoemulsion formulations. Droplet size 
(hydrodynamic diameter, dH) and polydispersity index (PDI) were measured 
by a Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., UK) at a fixed 
angle of 173° at 25 °C. The instrument contains a 4mW He-Ne laser (λ=633 
nm) and incorporates non-invasive backscatter optics (NIBS). 
Droplet size was determined by measuring the rate of fluctuation in laser 
light intensity scattered by Brownian motion of droplets. Translational 
diffusion coefficient was measured to calculate the droplet size using the 
Stokes-Einstein equation with the assumptions that spherical particles (the 
equivalent spheres) are in Brownian motion (Equation 3.1). 
 H  
kBT
   D
  (Equation 3.1) 
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Where kB is the Boltzmann constant; T is the absolute temperature; η is 
the dynamic viscosity of the continuous phase and D is the translational 
diffusion coefficient. The droplet size was calculated from the algorithms built 
into the software. Samples were appropriately diluted before measurement to 
avoid multiple scattering effects. 
In the construction of droplet size graphs, a break region from 25 to 100 
and log10 scale was used after the break up to 20,000. 
3.3.5.3 Physicochemical properties of nanoemulsion formulation 
Electrical conductivity measurement. The electrical conductivity (σ) of 
nanoemulsions was measured to evaluate conductive behavior using an S70 
SevenMulti™ conductivity meter (Mettler Toledo, Columbus, USA) fitted 
with an Inlab® 730 conductance electrode having a cell constant of 0.56 cm
-1
. 
Measurements were performed in triplicate at 25±0.5 °C. Calibration was 
performed using 0.01 M potassium chloride (KCl) as a standard solution. 
pH measurement.  The pH of nanoemulsion formulations was 
determined by a SevenMulti™ pH meter (Mettler Toledo, Columbus, USA) 
with a Mettler Toledo pH electrode (Inlab® SEMI-MICRO 51343164 97001-
638). The system was calibrated using pH 4.01, 7.00 and 10.01 pH buffer 
solutions (Mettler Toledo). 
Viscosity measurement. An Anton Paar viscometer (Model SVM 3000) 
was used to measure dynamic viscosity of nanoemulsion formulations at 25 °C. 
Refractive index measurement. The refractive index of nanoemulsion 
formulations was determined using a refractometer (Pocket PAL-RI 
refractometer ATAGO®, Japan) at room temperature. Approximately 0.3 ml 
of sample was placed on a prism surface to measure the refractive index. The 
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calibration of system was performed using deionized water at ambient 
temperature. 
Encapsulation efficiency.  The encapsulation efficiency of 
schizandrol A nanoemulsions was taken as the percentage of schizandrol A 
carried by the oil droplet (Equation 3.2). Free schizandrol A molecules in the 
nanoemulsions was determined by measuring the non-incorporated 
schizandrol A present in the aqueous phase after ultrafiltration/centrifugation 
using Centrisart
®
I centrifugal ultrafiltration devices (13239-E (10,000 D)). 1.5 
ml schizandrol A nanoemulsion was added to ultrafilter and centrifuged for 10 
min at 5000 rpm (Eppendorf 5810 centrifuge). The amount of schizandrol A in 
aqueous phase was assayed by the HPLC methods as previously described. 
The schizandrol A encapsulated in oil droplets was calculated from the 
difference between the total and the free schizandrol A concentration.  
Encapsulation efficiency (%) = 
     
  
x 100 (Equation 3.2) 
Where Ca is the concentration of schizandrol A detected in the aqueous phase 
and Ct is the total concentration of schizandrol A in the formulation. 
3.3.5.4 Microstructure studies 
Transmission electron microscopy (TEM). The morphology of 
selected nanoemulsion formulations was observed by transmission electron 
microscopy (TEM) using a FEI Tecnai G
2
 F20 S-twin/EDAX transmission 
electron microscope fitted with a CCD camera (Fei Corporation, Hillsboro, 
OR, USA). Two to three drops of nanoemulsion samples were placed on the 
film faces of 200 mesh formavar/carbon-coated copper-grids without dilution 
and negative stained with 3 wt% phosphotungstic acid (PTA) aqueous solution 
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subsequently. Excess solution was carefully blotted up with filter paper during 
each step. Samples were air-dried at room temperature for at least 12 hours.. 
All steps were conducted at room temperature. The sample was loaded into the 
TEM for imaging at 200 kV. TEM images were captured at magnifications 
ranging from low magnifications LM 2100x to SA 145000x image modes. 
Cryogenic field emission scanning electron microscopy (cryo-FESEM).
 Cryogenic Field emission scanning electron microscopy (cryo-FESEM) 
was performed to visualize particle morphology. Approximately 10 μl of 
nanoemulsion samples were deposited on a copper rivets and frozen in liquid 
nitrogen at -196 °C. Samples were then immediately transferred into the cryo-
preparation chamber (ALTO CT 2500, GATAN, UK) and freeze-fractured on 
the cryo-stage. The fractured sample was etched at -95 °C for 30 s and sputter-
coated with platinum for 180 s in the cryo-preparation chamber. The sample 
was then inserted into the field emission scanning electron microscope 
(FESEM, JEOL JSM-6700F, Japan) at -140 °C and examined at an 
accelerating voltage of 5.0 kV. 
3.3.5.5 Stability studies 
Physical stability on temperature and storage. The droplet size and 
polydispersity index of chosen nanoemulsions were analyzed from 5 °C to 
60 °C by DLS. Change in droplet size of chosen nanoemulsion formulations 
was monitored by DLS at 25 °C for one month. 
Chemical stability on storage. Nanoemulsion formulations containing 
schizandrol A were stored at room temperature. Concentration change of 
schizandrol A in the nanoemulsion formulations was studied using HPLC 
assay up to one month. 
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Thermodynamic stability studies. Nanoemulsion formulations were 
subjected to different thermodynamic stability tests. Selected formulations 
were centrifuged at 10,000 rpm for 30 minutes using a Centrifuge MiniSpin® 
(Eppendorf). Formulations which did not show any phase separations were 
taken for heating and cooling cycle treatment. Six cycles were run between a 
temperature of 4 °C and 50 °C for 48 hours, consisting of cooling at 4 °C for 
24 hours followed by heating at 50 °C for 24 hours were done and 
macroscopic appearance is observed. Observation of no phase separation or 
sedimentation is considered as a stable formulation. Stable formulations after 
6 cycles were subjected to the freeze-thaw cycle test. Three freeze-thaw cycles 
were tested in the temperature range from room temperature to -20 °C for 24 
hours that one cycle consist of 24 hours at room temperature then frozen at -
20 °C for 24 hours. Physical appearance was monitored to evaluate stability. 
3.3.6 In vitro permeation test 
3.3.6.1 Materials and equipment 
Synthetic membrane and reagents. Porous synthetic membrane 
selected for in vitro permeation study was a Tuffryn® polysulfone membrane 
(PALL Life Science, HT-450, P/N 66221). The membrane is 25 mm diameter 
with 0.45 µm pore size and 145 µm thickness (5.7 mils). The membrane 
porosity (ρ) is 80% and membrane tortuosity (τ) is ~1-1.5. Typical water 
permeation is 33 ml∙min/cm2 at 0.7 bar (70 kPa, 10 psi). Since the membrane 
is hydrophilic, pretreatment was carried out before permeation studies. 
Reagents used for membrane treatment were isopropyl myristate (IPM) and 
ethoxylate daliphatic amine (Ethomeen O/12LC). 
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Diffusion-cell system. Standard Franz diffusion cells of 15 mm-
diameter orifice (1.767 cm
2
 area; 25 mm total diameter of cell) with open cap 
and flat ground glass were used (Hansen Research, standard 7 ml vertical 
diffusion cell). A six-unit system was utilized (Start-up 6-Cell Manual Test 
System). The receptor phase was stirred using a constant spinning magnetic 
stir bar with a helix. The diffusion cell system was connected to a thermo 
circulator (Thermo Hakko Dc10-K10 Refrigerated circulator) to maintain 
constant temperature. 
Receptor phase. The medium used to collect the penetrated schizandrol 
in the receptor chamber was phosphate buffered saline (PBS), a physiological 
buffer solution with pH adjusted to 7.4, representing the pH of human blood. 
Isotonic PBS was prepared by dissolving 8.00 g NaCl, 0.20 g KCl, 1.44 g 
NaH2PO2∙H2O and 0.24 g KH2PO4 in 800 ml ultrapure water and the solution 
pH was adjusted to 7.4 using HCl. Then additional ultrapure water was added 
to adjust the volume to 1 liter. The prepared PBS solution was kept at room 
temperature. 
Treatment of synthetic membrane. Tuffryn® polysulfone membrane 
was impregnated with IPM/amine solution for at least 12 hours. The 
composition of the soaking solution is 15 wt% Ethomeen with 85 wt% IPM. 
Any excess solution was removed using absorbent tissue (Kimwipe). Prepared 
membrane was checked for holes, scratches, and other irregularities before 
placed onto the diffusion cell. 
Sample acquisition and data analysis. An Agilent HPLC system was 
used to analysis concentration of schizandrol A with a reversed-phase column 
and a 254 nm fixed-wavelength VWD detector. Experimental settings were in 
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accordance with the HPLC assay for the solubility studies. Agilent software 
was utilized to integrate peak area. 
3.3.6.2 Experimental 
The receptor chamber of diffusion cell was filled with PBS medium (pH 
7.4) using a syringe to fill through the check valve at the lower end and ensure 
there were no bubble formed during the filling procedure. Prepared membrane 
was placed on the center of the cell ring; gently tapping the side of the 
membrane to ensure that membrane stuck onto the ring without bubbles and 
the dosage wafer was placed on the membrane. Sample was then placed in 
position evenly distributed on the surface and covered by a glass disk. The cell 
ring was put on the donor compartment and clamped. Sampling tip was 
aligned 45° to the side. The cell system was stabilized to reach the operating 
temperature (37 °C). The system was under 500 rpm continuous stirring 
except during sample collection. Stirrers were turned off to collect samples. 
Medium was purged slowly into the diffusion cell to replace using a 1.0 ml 
syringe. The entire receptor fluid was withdrawn and replaced with fresh 
receptor medium (37 °C) at each sample collection. Samples were collected 
after 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours. Stirrers were turned on once 
sample collections were completed. The concentration of schizandrol A in the 
receptor medium was determined by HPLC without dilution. 
3.3.7 Statistical analysis 
All measurements were repeated at least three times and the data were 
reported as the mean ± standard deviation (S.D.). Means and standard 
deviations were calculated using Microsoft® Excel 2007. The statistical 
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analysis of the results was performed by one way ANOVA (analysis of 
variation) at the probability level of 0.05. A P value less than 0.05 was 
considered to be statistically significant. All statistical significance tests were 
two-tailed. The slopes were determined by linear regression, and their 95% 
confidence limits were calculated.  
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CHAPTER 4 RESULTS AND DISCUSSION 
 
4.1 Preformulation Characterization 









C-NMR were utilized to investigate molecular properties of schizandrol 
A. The liquid-state spectral investigations elucidated elemental and structural 
information and verified the chemical entity being schizandrol A. 
All data in Figure 4.1 and Figure 4.2 correspond to measurements for 
schizandrol A in CDCl3 solution and chemical shifts are in ppm relative to 
internal TMS. Based on Ikeya’s studies (Ikeya et al., 1988; Ikeya et al., 1980), 
schizandrol A falls in the schizandrin group with an R-biphenyl configuration 
and a hydroxyl group at C-7, and possesses a twist-boat-chair conformation. 
Our 
1
H-NMR results showed the following characteristic signals (δ in CDCl3): 
6.54 (H-4), 6.47 (H-11), 2.33 and 2.61 (H-6), 2.32 and 2.60 (H-9), 1.65 (C-7-
OH), 1.83 (H-8), 1.19 (C-7-Me), 0.76 (C-8-Me), 3.51, 3.82 and 3.83 (OMe). 
In the 
13
C-NMR spectrum (Figure 4.2), there are two methyl carbons of 
schizandrol A: axial secondary methyl C-17: δ 15.88 and equatorial tertiary 
methyl C-18: δ 29.84; C-7 with hydroxy group is seen at δ 71.83; other 
carbons are assigned as: aromatic rings δ 151.84, 140.74, 152.37, 110.39, 
131.81, 41.85, 133.86, 109.95, 152.05, 140.16, 151.55, 122.74, 124.18; 
benzylic methylene δ 40.80, 34.22; and methoxy carbons δ 60.96, 60.63, 55.99. 
The assignments of chemical shifts of schizandrol A were in agreement with 
data published by other researchers (Gottlieb et al., 1982; Ikeya et al., 1988; 
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C-NMR resonance signals of schizandrol A in CDCl3. The 




4.1.2 Phase analysis 
Powder X-ray Diffraction (PXRD) analysis. The characteristic 
diffraction pattern is obtained by crystalline phase interacting with X-rays. 
Powder X-ray diffraction pattern can serves as a fingerprint identification of a 
crystalline structure since the same structure always gives the same pattern. 
PXRD analysis was used to characterize and identify crystalline phases of 
schizandrol A. 
According to the PXRD diffraction study, schizandrol A powder pattern 
of scattering angles is presented in Figure 4.3. The sharp narrow diffraction 
peaks presented without wavy background represent the crystalline nature of 
schizandrol A. The typical corresponding d-spacing and relative intensities I/I0 
as percent relative intensity are listed in Table 4.1. The interplanar spacing (d) 




 (Equation 4.1) 
Where d is the distance between adjacent planes, n is an integer (n N*), λ 
is the wavelength of the incident wave, θ is the incidence angle. For the 
incident beam angle (θ) with respect to the sample plane, the diffracted ray is 
generated at 2θ with regard to the incident beam. 
Figure 4.3 is the diffraction spectrum of schizandrol A plotted by 
diffracted intensities versus the scattering angle (2θ). Three distinct identical 
peaks of schizandrol A were at 9.53°, 12.13° and 19.25° (2θ). The small 
number of diffraction peaks indicates relatively few atomic planes, 
characteristic of high symmetry cubic crystal nature of schizandrol A. The 
peak intensities at each scattering angle (Table 4.1) can be used to uniquely 




Figure 4.3 Powder X-Ray diffraction pattern of schizandrol A (CuKα, 35 
kV/40 mA). 
 
Table 4.1 Powder X-ray diffraction data of distinguished reflection peaks 
for schizandrol A. 
2θ (°) d (nm) I/I0 
9.53 0.928 100 
12.13 0.729 27 
14.46 0.612 9 
15.52 0.570 7 
16.24 0.545 4 
18.23 0.486 8 
19.00 0.467 8 
19.25 0.461 30 
21.20 0.419 5 
22.32 0.398 7 
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22.83 0.389 5 
23.89 0.372 7 
24.51 0.363 7 
26.55 0.335 9 
27.07 0.329 4 
29.11 0.307 4 
31.18 0.287 5 
2θ=twice the angle of incidence or diffraction. 
d=interplanar spacing. 
I/I0=percentages of the strongest line in the pattern (based on maximum 
intensity of 100). 
 
Fourier transform Infra-red (FTIR) analysis. FT-IR spectroscopy is 
used to get information on the structure of a compound or to assess the purity 
of sample. The mid-IR region (4000-400 cm
-1 
in wavenumbers) is of the 
greatest interest. Organic molecules absorb infrared radiation resulting in 
molecular vibrations. The energy of vibration matches the radiant energy and 
leads to absorption. 
Schizandrol A is stable enough to measure the IR-spectrum by pellet-
method using potassium bromide (KBr). The infrared spectrum provides 
valuable information about functional groups of schizandrol A. The FTIR 
spectrum (Figure 4.4) was plotted by transmittance (T) versus wavenumber 
(cm
-1
) that is number of waves per unit distance. 
From the characteristics of transmittance of schizandrol A (Figure 4.4), it 
is conclusive that schizandrol A has functional groups such as alcohol (–OH), 
methoxy group (R-O-CH3), alkyl group (C-H) and aromatic rings. Among the 





 suggesting the hydroxyl-group (O-H bond) of schizandrol A. Multi-
peaks lying between 3000-2800 cm
-1
 are the stretching vibrations from alkyl 
groups. Vibrations of Aromatic ring appear around 1600-1400 cm
-1
. The 
vibration absorption of methoxy groups can be seen from 1300 cm
-1
 to 1050 
cm
-1
 with the strongest C-O absorption at 1110 cm
-1
. The finger print region 
(~1400-200 cm
-1
) enables the identification of schizandrol A specifically. 
Similar FTIR spectra have been reported by others for schizandrol A, 
confirming our analysis (Gottlieb et al., 1982). 
 







4.1.3 Thermal analysis 
Thermogravimetric analysis (TGA). TGA measures weight loss of the 
sample as a function of temperature and thereby provides information such as 
water content, decomposition of a compound, gas evolution, and oxidation. 
TGA measurement showed the decomposition pattern of schizandrol A 
(Figure 4.5). The region up to 177 °C shows almost no weight loss indicating 
that schizandrol A is thermally stable up to this temperature. There was a 
change of only 1.5% in weight when sample of schizandrol A (initial weight 
4.735 mg) was heated from room temperature to 177 °C. The most dramatic 
weight loss occurred within the temperature range 177-271 °C which indicates 
the decomposition temperature range of schizandrol A. 
 
Figure 4.5 TGA spectrum of schizandrol A. 
 
Differential scanning calorimetry (DSC). DSC shows the change in 
heat capacity of the sample as a function of temperature and provides 
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information on transitions including melting, phase change and glass 
transitions. DSC can also be used to determine purity. 
The melting point of schizandrol A is approximately 131.58 °C according 
to DSC analysis (Figure 4.6). The extrapolated onset of the melting 
endotherm was measured to be 130.1 °C. Simultaneously, the molar heat of 
fusion (∆HF) of schizandrol A at the point of fusion (TF=404 K) was thereby 
determined, obtaining ∆HF=83.076 J∙g
-1
=8587.528 cal∙mol-1. Hence, the 
entropy of the solid at the fusion point was determined as ∆SF=∆HF/TF=21.256 
cal∙mol-1∙K-1. In addition, from the DSC thermogram (Figure 4.6), it can be 
observed that schizandrol A only has one distinct endothermic peak. The 
sharpness and shape of this endothermic event reveals that the schizandrol A is 
highly pure and the well defined melting peak suggests a predominantly 
crystalline behavior of schizandrol A. 
 





4.2 Phase Solubility Studies 
A nanoemulsion is composed of oil, surfactant, sometimes with the 
presence of cosurfactant, and water. The primary step in formulation 
development of a nanoemulsion system is the selection of these specific 
components. Mutual miscibility of these ingredients and their compatibility 
are important to produce a stable formulation. Since the nanoemulsion system 
here is designed for schizandrol A, it is essential that a desirable amount of 
schizandrol A can be soluble in an acceptable volume of nanoemulsion. 
Therefore, the capacity of each component to solubilize schizandrol A has to 
be determined and optimized. Micellization, cosolvency and complexation are 
proposed strategies to enhance the solubility of schizandrol A in aqueous 
phase. The oil phase was selected based on schizandrol A solubility in pure oil. 
The solubility of schizandrol A in pure water was 0.528±0.016 mg/ml 
determined by HPLC in this study. 
4.2.1 Solubility of schizandrol A by micellization 
Among the three categories of surfactant available, non-ionic surfactants 
were selected due to their low toxicity and non-irritating nature considering 
consumer demand for non-irritant products and consumer safety (Brandt et al., 
2011). For an oil-in-water nanoemulsion, non-ionic surfactant used should be 
hydrophilic in nature with a hydrophilic-lipophilic balance (HLB) higher than 
12 according to Griffin’s method (Griffin, 1946), to facilitate oil phase 
dispersed in the water-rich continuous phase. 
Micelles are formed when concentration of surfactant is above its critical 
micelle concentration (CMC). In a typical micelle system, a relatively non-
polar active ingredient can be solubilized in aqueous solution by incorporation 
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with micelles either adsorbed at micelle-water interface or dissolved in the 
hydrocarbon core of micelles. The location of the active ingredient depends on 
its polarity. Non-ionic surfactants usually have lower CMC values than ionic 
surfactants, which indicate the micelles formed are more stable upon dilution. 
In the present study, micellization was achieved by non-ionic surfactants, 
namely polyoxyethylene sorbitan esters (Tween 20, 40 and 80) and sucrose 
fatty acid ester (sucrose laurate, L1695). Polyethoxylated lipid derivatives 
(Tweens) and sucrose esters are widely used in pharmaceutical and cosmetic 
products as emulsifiers and stabilizers to improve solubility and stability of 
active ingredients. Tweens are fatty acids linked to repeating polyexthylene 
oxide units (typically 20) through ester linkages. Sucrose laurate used in this 
work is a sucrose fatty acid ester with HLB value of 16. Sucrose fatty acid 
esters are of natural origin which is preferred due to not only safety 
considerations and consumer preferences but also sustainability.  Sucrose 
laurate is a potential candidate for food, cosmetic and pharmaceutical 
applications because of its excellent biocompatibility and biodegradability, 
less sensitive to pH and temperature, although very high concentrations can 
lead to irritation and potential skin sensitivity (Garti et al., 1999; Kim et al., 
2009b). 
From the results (Figure 4.7), it can be seen that the solubility of 
schizandrol A in non-ionic surfactant solutions maintained a linear 
relationship with surfactant concentration. The relationship between total 
schizandrol A solubility (Stot), micelle concentration (CM), and surfactant 




Stot≈S0+ κCM≈S0+ κCsurf (Equation 4.2) 
Where Stot is the total solubility of schizandrol A. S0 is the intrinsic solubility 
of schizandrol A in water; CM is the concentration of micelles formed by 
surfactant; κ characterizes the solubilization capacity of the surfactant to 
solubilize the target hydrophobic active ingredient. It is defined as the amount 
of the solute (schizandrol A) that can be solubilized by one gram of micellar 
surfactant. It is of note that when the CMC is small, CM can be approximated 
to the total surfactant concentration (Csurf). For the non-ionic surfactants used 
in this study, their CMCs are such that CM can be regarded as Csurf. 
Therefore, the solubilization capacity of non-ionic surfactants can be 
determined by the linear regression of the concentration of schizandrol A 
against the surfactant concentration. The slope (κ) of solubility curves 
indicates the solubilization capacity of the surfactant and was listed in Table 
4.2. The results show that L1695 has the greatest capacity to solubilize 
schizandrol A in w/w concentration units. Within Tween series, Tween 80 




Figure 4.7 Solubilization of schizandrol A by micellization. 
 
Table 4.2 Properties and solubilization capacity (κ, mg/g) of non-ionic 
surfactants for schizandrol A. 
Non-ionic surfactant HLB CMC (mM) κ R2 
L1695 16 ~0.33 48.553±1.420 0.997 
Tween 80 15 0.012 30.252±0.961 0.997 
Tween 40 15.6 0.027 28.265±0.549 0.999 
Tween 20 16.7 0.08 26.884±0.546 0.999 
 
The difference in solubilization capacity between L1695 and Tweens can 
be attributed to their different polar head groups (Figure 4.8). It is apparent 
that the hydrophilic head group played a crucial role in solubilizing 
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Figure 4.8 Chemical structures of non-ionic surfactants. (A) sucrose 
monolaurate; (B) Tween 20; (C) Tween 40; (D) Tween 80. 
 
The head group of surfactants primarily controls micelle growth at both 







to move closer to each other in order to reduce the available area per surfactant 
molecule at the micelle surface from a thermodynamic point of view, while 
the steric interactions between head groups pose an opposing repulsive force 
to the micellization process. Consequently, the intermolecular hydrogen 
bonding between the ether oxygen and hydroxyl groups of nonionic 
surfactants and water molecules are important factors. 
Moreover, micelle hydration is a major factor in stabilizing nonionic 
micelles, preventing their coacervation and aggregation. The extent of 
hydration of spherical micelles is governed by geometrical factors. 
For the polyoxyethylene (POE) head group of Tweens, coils of hydrated 
POE chains are present in the outer region in order to maximize contact with 
water. The water-excluded interior of the micelle containing the hydrophobic 
groups presents a radius of approximately the length of the fully extended 
hydrophobic chain in order to minimize contact with water. The aqueous 
solubility of POE surfactants results from hydrogen bonding between the ether 
oxygen of the ethylene oxide chain and water molecules. The first few 
methylene groups adjacent to the head are considered in the hydration sphere 
due to the aqueous phase penetrating into the micelle beyond the hydrophilic 
head groups (Rangel-Yagui et al., 2005). Water is trapped in a larger amount 
in the mesh of tangled POE chains. Therefore, it is very likely that the water 
trapped by the POE chain mesh physically hinders the uptake of schizandrol A 
molecules hence decreases the solubilization efficiency. 
In contrast, sucrose fatty acid esters such as L1695 are carbohydrate-
based surfactant having a disaccharide as a polar head group. This polar head 
group is known to have a close-packed configuration at the interface. As a 
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result, the extent of interaction with a more flexible POE mantle is greater than 
that of the compact hydrophilic ring-type head of sucrose, leading to increased 
micellar hydration. The increase in micellar hydration thus results in the 
decrease in capacity to solubilize schizandrol A. 
With respect to Tween series, the slope indicating the solubility capacity 
of Tweens to solubilize schizandrol A is slightly greater in the case when the 
hydrophobic tail moiety is increased with constant POE units (CnSE20). The 
general structure CnSE20 represents the ethoxylated derivatives of sorbitan 
ester (S indicates the sorbitan nature, n and 20 denote the alkyl and ethylene 
oxide chain length). This is in agreement with the general rule that the larger 
non-polar region solubilizes more solute. It is also supported by the fact that 
the longer hydrophobic moiety, the larger the micelle size, the stronger 
tendency towards association, the lower the CMC value, and thus more 
enhanced solubilization. However, the increase is not very significant in this 
case. 
The relative hydrophobicity can be illustrated by the HLB values of 
Tweens which follows the trend Tween 20 (16.7) < Tween 40 (15.6) < Tween 
80 (15). With the same functional head group, the reduction in HLB value is 
ascribed to the increment in hydrocarbon tail group. From Tween 40 to Tween 
80, methyl groups and an unsaturated single double bond are added, which 
causes the double bond effect to the system. This stereochemical change can 
be used to explain why there was only a small increase in solubility capacity 
from Tween 40 to Tween 80. 
Assessment on the basis of surfactant solubilization capacity suggests that 
sucrose laurate is the best solubilizing agent for schizandrol A attributed to its 
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compact head group less hydrated than the head group of polysorbates. The 
solubility capacity follows the order L1695 > Tween 80 > Tween 40 > Tween 
20 (Table 4.2). The solubility of schizandrol A was affected by micellar 
hydration to a greater extent than by hydrocarbon chain length. Solubilization 
of schizandrol A by micellization decreases with increased micelle hydration. 
Similar phenomena have been reported by Elworthy (1962) on 
polyoxyethylene surfactants and Barry and El Eini (1976) on the study of 
steroids (Barry, 2001b; El Eini et al., 1976; Elworthy and Macfarlane, 1962). 
Though there was only a very small increment with increasing in 
hydrophobicity of Tweens, schizandrol A solubility increases with increased 
hydrocarbon chain length. 
In this study, packing of the monomer into micelles and hydrophilicity of 
the hydrophilic group of non-ionic surfactant affected the extent of schizandrol 
A solubilization. Therefore, it is reasonable to expect that a nonionic 
surfactant with a less hydrated hydrophilic head group would be suitable for 
schizandrol A as a solubilizing agent. 
4.2.2 Solubility of schizandrol A by cosolvency 
Cosolvency is another traditional and powerful way to overcome the 
solubility limitation of poorly water-soluble compounds. Cosolvents 
commonly used are hydrophilic molecules but less polar than water in order to 
alter the polar environment in the water phase to favor the non-polar solute. 
The hydrophobic aspect of the cosolvent will interfere with the hydrogen 
bonding network in water, disrupting self-association of water, easing the 
overall intermolecular attraction of water thus enhance the solubilization. 
Cosolvents chosen for this study were those most pharmaceutically relevant: 
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ethanol (EtOH), propylene glycol (PG), glycerin (GL) and polyethylene glycol 
(PEG) in a range of molecular weight from 200 to 8000 gmol
-1
. 
Over and above the ability of these cosolvents to improve the 
hydrophobic ingredient solubility, they have additional benefits for topical 
applications (Benson, 2005; Williams and Barry, 2012). Ethanol can be 
regarded as a skin permeation enhancer because it distorts the structure of the 
skin layer to facilitate the transport of active substance through it. Propylene 
glycol is considered to be a humectant ingredient in cosmetic products. It has 
humectant properties, attracting water from the viable dermis into the 
epidermis, and emollient properties that prevent barrier damage when applied 
to skin, although it can be an irritant. Glycerin is also a humectant and 
emollient that can be used as a moisturizer and treatment for medical 
conditions of the skin without irritation. Glycerin is capable of maintaining 
water balance, promoting skin cell maturation, and providing a healthier, 
natural-looking skin. PEG has been found to open the pores of the skin 
enabling the penetration of external chemicals through the skin. However, 
PEG may cause allergic reactions under exposure to strong sunlight and 
maybe irritating to damaged skin (Fruijtier-Pölloth, 2005). 
In a cosolvent system, the solubility of a non-polar substance in solvent 
mixtures composed of water and an organic cosolvent can be described by a 
log-linear relationship (Equation 4.3) with the assumption that the solute is 
not changed at the macroscopic level by the cosolvent, for example through 
solvate formation or alternation of crystal structure (Millard et al., 2002). 
LogStot=LogS0+σC (Equation 4.3) 
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Where Stot is the total solubility of the substance, S0 is solubility of the 
substance in water. σ is the capacity of the cosolvent to solubilize the 
substance. The solubility of schizandrol A changes exponentially as a function 
of volume fraction concentration of the cosolvent in the water-cosolvent 
binary system. The enhancement of solubility of schizandrol A in aqueous 
phase follows the order: ethanol > PEG 400 > propylene glycol > glycerin 
(Figure 4.9). 
 





Figure 4.10 Solubilization of schizandrol A by PEGs. 
 
Table 4.3 Solubilization capacity (σ) of cosolvents for schizandrol A. 
Cosolvent σ R2 
Ethanol 4.403±0.103 0.998 
Propylene glycol 1.809±0.057 0.997 
Glycerin -0.346±0.042 0.958 
PEG 200 2.035±0.047 0.998 
PEG 400 2.165±0.061 0.998 
PEG 1000 2.397±0.072 0.997 
PEG 4000 2.417±0.058 0.998 
PEG 6000 2.441±0.043 0.999 




In cosolvency, the most important factor is the polarity match between 
solute and solvent. The trend of solubilization capacity of cosolvents can be 
illustrated by polarity parameters including dielectric constant (ε), 
hydrophobicity (expressed as the octanol-water partition coefficient, logP) and 
interfacial tension (γ). These indexes, which reflect cohesive properties and 
solubilization behavior of the compound in solution, are strongly correlated 
(Yalkowsky, 1999). The polarity parameters that best represent the solvent 
activity coefficient are expected to give the best correlation with slope of the 
solubilization curves. 
Table 4.4 Cosolvents properties (at ambient temperature) and their 

















Ethanol 24.3 -0.24 0.5 12.7 4.403±0.103 
PEG 400 12.4 -4.8 11.7 11.3 2.165±0.061 
Propylene 
glycol 
32 -0.92 12.4 12.6 1.809±0.057 
Glycerin 42.5 -1.76 32.7 17.7 
-
0.346±0.042 
Water 78.36  45.6 23.4   
a
Source: Babu et al., 2008. 
b
Source: Hansch et al., 1995. 
c
Source: Rubino and Yalkowsky, 1987. 
d
Source: Barton 1991. 
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Among these polarity parameters, the best correlation between cosolvents 
used and solubilization of schizandrol A was obtained with interfacial tension 
(Table 4.4). Interfacial tension has been proven to be a pivotal parameter for 
studying the solubility of hydrophobic solutes and aqueous solutions, since it 
reflects the total polarity of the solvent. A decrease in interfacial tension offers 
increasing favorable dispersion interactions with the solvent molecules. 
The solubilization efficiency of a cosolvent depends on the water-
cosolvent interactions. Therefore, the increasing solubilization capacity for 
less polar cosolvent can be explained by the fact that the less polar the 
cosolvent, the more effective it is at disrupting hydrogen bonding interactions 
between water molecules, providing a more favorable environment for 
schizandrol A incorporation. A higher logP value indicates a stronger affinity 
to water and a weaker hydrophobic effect thus promoting the solubilization of 
a hydrophobic compound such as schizandrol A. Similarly, a less polar 
cosolvent with a lower dielectric constant and a lower interfacial tension leads 
to enhanced schizandrol A solubilization. 
Furthermore, based on the ‘cavity model’ developed by Amidon (1974), 
solubilization in water is driven by solute-water interactions and free energy 
penalty to build the cavity around the solute. The cavity defines a volume that 
can no longer be populated by water molecules. To build a cavity around the 
solute is energetically unfavorable due to entropy loss of water and a partial 
loss of favorable water-water interactions. Certain losses increase with 
increasing molecular size. As a consequence, an absence of strong water-water 
interactions induced by a cosolvent will dominate the overall trend. 
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The resultant effect of cosolvent on schizandrol A solubility depends on 
the actual balance between the favorable component from dispersion 
interactions and the unfavorable component from cavity formation. 
PEGs possess the same type of function groups, hence similar logP values 
and possible interactions with either water or solute can be expected. Although 
the difference in their ability to assist schizandrol A solubilization is not 
distinguishable, the marginal difference can be accounted for by the 
enlargement of the ethylene oxide groups (Figure 4.10). 
Surprisingly, glycerin showed unusual behavior in that it slightly 
decreased the solubility of schizandrol A in water. This kind of phenomenon is 
occasionally observed in developmental studies where the addition of organic 
cosolvents caused a decrease in the aqueous solubility of poorly soluble active 
substances. It has been reported that in the presence of glycerin, the solubility 
of phenytoin (PHT) in aqueous decreased and the minimum solubility was 
found at around 10% (w/v) of glycerin by Kawakami and coworkers 
(Kawakami et al., 2004; Kawakami et al., 2006). The low solubilizing 
potential of glycerin may be due to its strong interaction with water through it 
hydroxyl groups and greater integration into the water structure better than 
other cosolvents. 
The incompatibility between schizandrol A and glycerin can be explained 
by cavity formation. The solubility of a substance is affected by the 
conformation of the molecules. The macroscopic solubility would in principle 
reflect a Boltzmann-weighted conformation distribution of the compound in 
solution. When comparing the different cosolvents, the ability to compensate 
the free energy penalty for cavity formation is greater for less polar cosolvents 
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due to the fact that their reduction of interfacial tension effectively 
counterbalances the effect of water molecules squeezing out the poorly soluble 
substance. The solvation free energy of schizandrol A is less favorable in 
water-glycerin than other water-cosolvent binary system. This can be 
attributed to decrease in the cavity size and the respective formation. The 
aggregation of cosolvent molecules may not be sufficient to provide 
homogeneous water-cosolvent mixtures. This has a profound impact for 
interpreting the change in solubilization behavior caused by cosolvency. 
With the aid of cosolvents, a more favorable solvation of schizandrol A is 
created in the aqueous phase except for glycerin. Solubility of schizandrol A 
in water-rich mixed binary systems is a linear and logarithmic function of 
cosolvent content. Moreover, the observations suggest that the effectiveness of 
solubilization for schizandrol A in water is a function of the cosolvent polarity, 
thus highest solubilization capacity was produced by the least polar cosolvent 
studied. Glycerin present in the binary system competed with the schizandrol 
A molecules rather than perturbing the water network structure causing an 
anti-solvent effect. 
4.2.3 Solubility of schizandrol A by complexation 
Complexation improves the solubility of solute molecules owing to the 
formation of a water-soluble inclusion complex (Connors, 1997; Loftsson and 
Brewster, 1996; Loftsson and Duchene, 2007). Cyclodextrins are a group of 
cyclic oligosaccharides obtained from enzymatic degradation of starch. 
Cyclodextrins (CDs), cyclic oligosaccharide molecular hosts, have a toroidal 
structure with primary and secondary hydroxyl groups orientated outwards, 
forming a hydrophilic exterior and hydrophobic internal cavity. This cavity 
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provides a microenvironment to solubilize hydrophobic molecules or 
hydrophobic parts of molecules. Poorly water-soluble compounds (guests) can 
enter into this cavity and form an apparent guest/host complex (Figure 4.11). 
CDs and their derivatives are composed of 6 to 8 (α-1,4)-linked α-D-
glucopyranose units forming a rigid, torus-shaped conformation with a central 
hydrophobic cavity of the size 5 to 8 Å. Factors that affect solubility capacity 
are the type, length, and degree of substitution of cyclodextrins. 
Cyclodextrins used in this study are β-CD and γ-CD composed of seven 
and eight D-(+)-glucopyranose units respectively (Figure 4.12). Their 
derivatives, HP-β-CD and HP-γ-CD were also employed to study the effect on 
solubilization of schizandrol A because they are more water-soluble and less 
toxic entities. Physical properties of cyclodextrins are listed in Table 4.5. 
 






Figure 4.12 Chemical structures of complexants. (A) β-cyclodextrin (β-CD); 
(B) γ-cyclodextrin (γ-CD); (C) 2-hydroxypropyl-β-cyclodextrin (HP-β-CD); 
(D) 2-hydroxypropyl-γ-cyclodextrin (HP-γ-CD). 























β-CD 7 1135a 1.85a 6.0-6.5a 15.4b 7.9b 262c 
HP-β-CD 7 1400 
     
γ-CD 8 1297a 23.2a 7.5-8.3a 17.5b 7.9b 427c 
HP-γ-CD 8 1580           
 
a
 Source: Loftsson and Brewster, 1996. 
b
 source: Bekers et al., 1991. 
c




In this study, schizandrol A formed apparent 1:1 guest/host complex can 
be assumed by the monotonic increase as a function of complexant 
concentration as shown in Figure 4.13. The apparent stability constant of each 
complex is determined to indicate complexation efficiency and used to 
compare the affinity of schizandrol A for complexants. The apparent stability 
constants (K1:1) of schizandrol A/complexant 1:1 complex were calculated 
from Equation 4.4 (Higuchi and Connors, 1965). 
     
 
S0      
 (Equation 4.4) 
Stot = S0+τCCD   (Equation 4.5) 
In this equation, K1:1 denotes the stability constant; τ denotes 
solubilization capacity expressed as the slope of the solubility curve 
(Equation 4.5); S0 denotes the intrinsic solubility of the compound in water; 
Stot denotes the total schizandrol A solubilized; and CCD denotes the 
concentration of complexant. Figure 4.13 shows the solubility profile of 
schizandrol A by complexation with cyclodextrins. The solubility of 
schizandrol A increased almost linearly with increasing concentration of CDs 
suggesting a AL-type system, the formation of a 1:1 schizandrol A/CD 
complex in solution. The solubilization capacity and stability constant are 
listed in Table 4.6. In most cases, the observed value of K1:1 is between 50 and 
2000 M
-1
 with a reported mean value of 490 and 355 M
-1
 for β-CD and γ-CD 
respectively (Connors, 1997). However, K1:1 evaluated in schizandrol A/CD 
complexation is relatively small. The results indicate that schizandrol A and 
CDs cannot form an inclusion complex efficiently. The low efficiency of 
complexation inclusion can be explained by the mismatch in hydrophobicity 





Figure 4.13 Solubilization of schizandrol A by cyclodextrins. 
 
Table 4.6 Solubilization capacity (τ) and stability constant (K1:1, M
-1
) of 
cyclodextrins for schizandrol A. 
Cyclodextrin τ (x10-3) R2 K1:1 
β-CD 4.910±1.0814 0.908 4.042 
HP-β-CD 5.640±0.23517 0.991 4.646 
γ-CD 4.130±0.18045 0.991 3.397 
HP-γ-CD 4.820±0.120 0.997 3.968 
 
The driving forces of complex formation are the exclusion of high energy 
water from the cavity, hydrogen and hydrophobic bindings, and van der Waals 
interactions. The ability of hydrophobic guest molecules to fit well into the 
empty cavity of host plays a vital role in the formation of the inclusion 
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complex. Steric fit and hydrophobic match are regarded as the main factors 
controlling efficiency of complexation inclusion. 
Fitting into the CD cavity requires three types of interactions: steric, 
electrostatic and hydrophobic interactions (Náray‐Szabó, 1993). Steric fit 
means that interacting atoms should be within their van der Waals radii to 
avoid aggregation and the cavity should be filled densely, favored by entropy 
that reduces the free space between interacting atoms to a minimum. Steric 
complementarity is endorsed by the binding capacity. It is known that host and 
guest should avoid steric conflicts to ensure a stronger binding affinity (Náray
‐Szabó, 1993; Saenger and Steiner, 1998). 
Electrostatic interactions are the ionic and polar interactions such as 
hydrogen bonding and dipole-dipole type attraction between the host and guest. 
The greater the interaction is, the more efficient the inclusion will be. The 
electrostatic interactions are less important for non-ionic surfactants in this 
study. Hydrophobic interactions take place between non-polar groups. The 
diameter of the CD ring can be controlled by the number of glucose molecules 
in the chain. 
Therefore, the low solubilization capacity of cyclodextrins to solubilize 
schizandrol A is because of low accessibility of schizandrol A to the CD 
cavity. The immiscibility of schizandrol A in the cavity of the cyclodextrins 
and steric effects based on molecular geometries of the components restrict the 
inclusion thus result in low efficiency of complexation. 
However, though the cyclodextrins did not exhibit expected solubilization 
capacity by complexation, the small amount of increase in solubility of 
schizandrol A can be contributed to their hydrotropic effect. The increase of 
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the apparent solubility of a hydrophobic substance in aqueous solution is 
attributed to the addition of a third substance that changes the solution 
environment. 
4.2.4 Solubility of schizandrol A in combination 
The combined use of micellization, cosolvency and complexation 
methods has received great attention due to their efficient solubilization, 
stabilization and transportation capabilities (Kawakami et al., 2006; Strickley, 
2004). In many cases, combinations of solubility enhancement methods not 
only provide synergistic effect, but also minimize the concentration of each 
component required to reach the desirable solubilization or dissolution with 
reduced toxicity. 
The effectiveness of a combination strongly correlates to the 
physicochemical properties of these solubilizing agents and the interactions 
between them. The solubility of schizandrol A was studied in mixed micelles, 
cosolvent system with L1695, and with cyclodextrin derivatives (HP-β-CD 
and HP-γ-CD). The solubility of schizandrol A was measured in solutions of 
mixtures at a constant ratio 1:1 (w/w) of each additive with a total 
concentration of 2, 10 and 20 wt%. 
4.2.4.1 Mixed micelles 
A mixed micelle system can be used to exploit the synergistic behavior, to 
control the physical properties and to improve the stability of the formulation 
(Holland and Rubingh, 1992). Studies reveal that certain mixtures of 
surfactants can provide better performance than a single surfactant for a wide 
variety of applications. It is also known that non-ideal mixing of surfactants 
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results in enhanced solubilization and stability because of lower CMC and 
lower interfacial tension. Although synergism in surfactants is often observed 
in dissimilar surfactants (e.g. ionic surfactant with non-ionic surfactant), 
improvements in properties may also occur with mixtures of surfactants 
possessing similar structures (i.e. synergism in non-ionic surfactant mixtures). 
Compared to single surfactant systems, all mixed surfactant systems 
showed enhanced solubility of schizandrol A as seen in Figure 4.14. Their 
capacities to solubilize schizandrol A are listed in Table 4.7. 
 




Table 4.7 Slopes of solubilization profiles for schizandrol A by combined 
methods. 
Combinations (1:1) slope R2 
L1695 : Tween 80 42.492±4.027 0.973 
L1695 : Tween 40 34.722±0.136 0.996 
L1695 : Tween 20 32.659±1.123 0.996 
L1695 : Ethanol 28.662±1.446 0.992 
L1695 : Propylene glycol 27.831±1.165 0.995 
L1695 : PEG 400 26.470±0.942 0.996 
L1695 : HP-β-CD 20.618±0.559 0.998 
L1695 : HP-γ-CD 26.085±0.401 0.999 
 
The trend for solubility of schizandrol A in mixed micelles followed the 
order: L1695/Tween 80 > L1695/Tween 40 > L1695/Tween 20. Mixtures of 
L1695 and Tween 80 displayed a greater solubilization capacity than other 
mixtures at a concentration higher than 10%. Among the single surfactants 
studied, L1695 with an HLB of 16 achieved the largest solubility of 
schizandrol A in water. It should be noted that the best mixture, Tween 
80/L1695, did not solubilize more than L1695 alone at the same weight 
percentage level. 
In this study, the impact on schizandrol A solubilization of the mixture of 
L1695 and Tweens, is mainly dependent on intermolecular interactions. The 
effective HLB values of mixed micellar system are listed in Table 4.8. There 
is no significant difference in HLB values of the mixed surfactant system. 
These findings are in agreement with the study of single surfactant systems 
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that solubilization of schizandrol A by micellization is more dependent on 
micelle formation than hydrophobicity. When L1695 was mixed with 
polysorbates in fixed proportions, the interaction between the head groups 
influenced micelle formation. L1695 has a large equilibrium potent 
hydrophilic polar head and a shorter absolute hydrophobic tail (smaller 
lipophilic volume) giving a small value of packing value. 
Table 4.8 HLB values of mixed micelles. 
1:1 L1695 Tween 80 Tween 40 Tween 20 
Tween 20 16.35 15.85 16.15 16.7 
Tween 40 15.8 15.3 15.6 - 
Tween 80 15.5 15 - - 
L1695 16 - - - 
 
For Tween 80, the double bond in the oleic acid ester of the hydrophobic 
tail results in a bend in the hydrophobic chain. This bending chain leads to a 
larger lipophilic volume with an increased packing value. This larger packing 
value of Tween 80 may affect the mixed micelle formation with L1695. When 
surfactants were employed at a higher concentration, i.e. 20 wt% L1695 : 
Tween 80 (1:1), there was no apparent synergistic effect between these two 
surfactants. The solubility of schizandrol A in this system appeared to 
approximately equal the sum of schizandrol A solubility in 10% Tween 80 and 
10 % L1695 aqueous solutions. The linear nature of the schizandrol A 
solubility indicates its almost ideal behavior for mixed micelle formation 
under such conditions. The ideal behavior of a mixture of non-ionic 
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surfactants follows the Clint relation considering the stoichiometric molar 
fractions of the two components in the mixture (Clint, 1975). 
The solubilization behavior of schizandrol A in mixed micelles was not 
significantly improved due to the limited synergistic effects resulting from the 
minimum intermolecular interactions. 
4.2.4.2 Combination of sucrose laurate and cosolvent 
Addition of a cosolvent to surfactant solutions affects the interaction 
between the surfactant molecules. It alters the bulk phase of the solution and 
potentially provides a better solvent environment for the surfactant molecules. 
Hence, the movement from the bulk phase into a micellar phase of the 
hydrophobic tail of a surfactant become less favorable and thereby makes the 
aggregation process of surfactants less spontaneous (Zana, 1995). For instance, 
adding cosolvents into surfactant solutions will increase CMC value of 
surfactants due to solubilization of the surfactant monomer by the cosolvents. 
Moreover, some less polar cosolvents may incorporate into the micelles to 
some degree causing changes in the characteristics of the aggregates. 
Therefore, the compatibility of cosolvents with surfactant and the active 
ingredient can be estimated, though greatly improved solubilization cannot be 
expected by a combination of surfactant and cosolvent. The solubility of 
schizandrol A in micelle-cosolvent-water mixtures was investigated to study 
the effect of cosolvent on sucrose laurate. 
The solubility of schizandrol A was elevated by the cosolvents used as 
compared with L1695 alone. The addition of cosolvent did not reduce the 
capacity of L1695 to solubilize schizandrol A. As investigated above, both 
micelle and cosolvents individually contributed to the solubilization of 
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schizandrol A. When ethanol and propylene glycol were added, an increase in 
the solubility was observed, while the addition of PEG400 had only a minor 
impact on the solubility (Figure 4.15). 
 
Figure 4.15 Solubilization of schizandrol A in L1695 : cosolvent (1:1) 
system. 
 
There are two possible ways that the addition of cosolvents affects the 
micelle properties of surfactant solutions. One is by specific interaction with 
the surfactant molecules and the other is through changing the nature of the 
solvent (Nagarajan and Wang, 2000; Zana, 1995). Solubility enhancement of 
schizandrol A by micellization is caused by partition of schizandrol A 
molecules into micelles formed by L1695 whereas such enhancement by 
cosolvency is caused by changes in the bulk properties of the isotropic 
solution. 
The cosolvents used in this study have a permittivity (static dielectric 
constant, ε) lower than water. As a result, when L1695 was mixed with 
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cosolvent, the cosolvent is expected to penetrate the micelles, change their 
structure and affect the micellization process. The hydration state of sucrose 
head group of L1695 may be affected by replacing bonded water with another 
solvent molecule such as ethanol. However, the interaction between L1695 
and cosolvent at the interface does not favor a significant amount of 
schizandrol A to penetrate into the hydrophobic core of the micelle when 
compared to L1695 alone. This may due to the capacity of hydrophobic core 
of L1695 to absorb schizandrol A. 
4.2.4.3 Combination of sucrose laurate and cyclodextrin 
Both micellar core of surfactant molecules and hydrophobic interior of 
cyclodextrin molecules provide a solubilization site for hydrophobic 
compounds when they are used in combination. However, there are cases 
where the solubility of hydrophobic compounds decreases in such mixtures 
compared to single solubilizing agent systems due to inclusion complex 
formed by the surfactant and CD competing with hydrophobic active 
ingredients. 
The solubility of schizandrol A in L1695 and cyclodextrin derivative 
mixtures is shown in Figure 4.16. The combinations of complexant and 
L1695 showed increased schizandrol A solubility with increasing 
concentration. L1695 used with HP-γ-CD showed a higher solubility of 
schizandrol A than L1695 with HP-β-CD. It is evident that L1695 did not 
interact strongly with CDs with respect to their solubilization capacity for 
schizandrol A. If there was a strong interaction between the CD cavity and the 
hydrophobic chains of L1695, breakup of micelles would take place based on 
a change in the surrounding media and the micelle size would consequently 
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become smaller than in the single surfactant system. Therefore, the results 
indicate that the micelles formed by L1695 stay intact, to some extent. As 
previously investigated, complexants showed limited influence on the 
solubility of schizandrol A, when complexant used with L1695, HP-γ-CD 
exhibited a better solubility profile than HP-β-CD. This may be ascribed to the 
interaction of complexant with sucrose laurate and sucrose laurate takes the 
main responsibility to solubilize schizandrol A. 
 
 
Figure 4.16 Solubilization of schizandrol A in L1695 : cyclodextrin (1:1) 
system. 
 
Schizandrol A cannot effectively be incorporated into the CD cavity as 
previously investigated, and complexant inclusion with L1695 might take 
place as a result of the formation of a complex as CD concentration increases. 
HP-γ-CD has a slightly larger cavity size than that of HP-β-CD and the 
interaction with hydrocarbon chains may be weaker because the larger binding 
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constants result from stronger van der Waals attraction between complexant 
and guest molecule. The decrease in surface tension and hence increase in 
CMC can also be explained as a solvent effect and is not necessarily due to an 
interaction between surfactants and CDs because of a hydrotropic effect. 
Comparison between complexants, HP-γ-CD bearing a larger hydrophobic 
space performed better than HP-β-CD. 
4.2.5 Solubility of schizandrol A in oils 
Oil candidates in this work are of pharmaceutical or food grade. Ethyl 
butanoate and ethyl octanoate are flavor oils. Ethyl butanoate is a colorless 
ester with a fruity odor, similar to pineapple. It is commonly used as an 
artificial flavoring in beverages and as a solvent in perfumery products. It is 
slightly soluble in water as 4900 mg∙L-1 at 20 °C. Ethyl octanoate is also a 
flavor and fragrance agent. Isopropyl myristate (IPM) and isopropyl palimitate 
(IPP) are emollient esters of low viscosity that lubricate and soften the skin. 
Oleic acid is considered as a penetration enhancer through a mechanism 
involving stratum corneum lipid fluidization and phase separation (Williams 
and Barry, 2012). Triacetin has been stated as having activities as 
percutaneous absorption accelerator and antifungal agent (Allen, 1990; Quan 
et al., 1997). It is reported that triacetin does not induce skin irritation or skin 
sensitization (Fiume, 2002). Given that the selected oil candidates are known 
in the art of penetration enhancement, it is necessary to choose the best oil 




Figure 4.17 Schizandrol A solubility in oil phases. (IPP: isopropyl palmitate; 
IPM: isopropyl myristate; CO: castor oil; EO: ethyl oleate; OA: oleic acid; 
EnO: ethyl octanoate; EnB: ethyl butanoate). 
 
In the present study, solubility of schizandrol A in a variety of oils was 
tested to select the most suitable oil in terms of the optimum solubility of 
schizandrol A. The solubility of schizandrol A was found to be highest in 
ethyl-n-butanoate (EnB) compared to the other oils (Figure 4.17). This can be 
attributed to the polarity of schizandrol A that favors its solubilization in small 
or medium molar volume oils such as ethyl butanoate, triacetin and ethyl 
octanoate. Comparatively far lower solubility of schizandrol A was observed 
in the IPP, IPM, castor oil and ethyl oleate. This may be ascribed to the 
general rule that poor ability of edible oils to dissolve large amounts of 
lipophilic active ingredients (Fanun, 2010). 
Within non-polar compounds, the intermolecular attraction comes from 
the very weak induced dipole forces. The weak attractive force among solute-
solvent molecules compensates for breaking the weak bonds in the non-polar 
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substances. Recently, studies have revealed that smaller molecular volume oils 
(fatty acid chain length in the range of C8-C12) have a larger capacity to 
solubilize poorly-water soluble active substance with the additional advantage 
of easy emulsification. Based on this study, ethyl butanoate was selected as the 
oil phase for the development of nanoemulsion. 
4.2.6 Stability of schizandrol A in aqueous solutions 
The stability of schizandrol A in aqueous solutions was studied based on 
two model aqueous solutions: 10% L1695 : Propylene glycol (1:1) and 10% 
L1695 : PEG 400 (1:1) in water. L1695 was regarded as the main surfactant 
forming micelles in the aqueous phase at concentration above CMC. 
Propylene glycol and PEG 400 were regarded as cosurfactant to facilitate the 
solubilization of hydrophobic compound and impact on the interface. 
Propylene glycol and PEG 400 were selected as cosurfactant. The control was 
a ethanol-water mixture (1:1). The concentration of schizandrol A was 1 
mg/ml for all test samples. 
4.2.6.1 Effect of temperature and storage time 
The effect of temperature on solutions containing schizandrol A was 
investigated by means of droplet size and polydispersity index (PDI) analysis 
using DLS technique. 
The stability of formulation can be studied by monitoring the change in 
droplet size and PDI. The physical stability of the formulation was indicated 
by a change in droplet size and transparency. Figure 4.18 illustrates the 
impact of temperature on the droplet size and PDI value at different 




Figure 4.18 Hydrodynamic diameter and polydispersity index (PDI) of 
micelle containing schizandrol A in 10% L1695 : PG (1:1) and 10% L1695 : 
PEG 400 (1:1) aqueous solutions. 
 
The effect of temperature on the stability of micelles made from non-ionic 
surfactant is an important variable due to the potential susceptibility of a non-
ionic surfactant to change as temperature changes resulting in destabilization 
of the interface and structural transitions. As seen in Figure 4.18, the average 
hydrodynamic diameter is in the range of 10.3-11.3 nm for L1695: Propylene 
glycol) and 9.5-10.5 nm for L1695 : PEG 400, the PDI value ranged around 
0.2 for L1695 : PG and from 0.13 to 0.16 for L1695 : PEG 400 indicating a 
mono-disperse system. Studies suggested that the aggregation number of 
sucrose monolaurate does not increase significantly with temperature 
(Herrington and Sahi, 1986). The slightly decreasing trend in droplet size of 
the samples may be caused by the interaction of micelles with cosurfactant 
and/or schizandrol A molecule resulting in shrink in micelle corona when 
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temperature is increased. Although sucrose-water attraction is known as 
decreasing only slightly with increasing temperature, addition of other 
ingredients which will prevail with sucrose laurate micelle may cause the 
softening of hydrogen-bonding of water molecules at high temperature that 
affects the micelle hydration (coronal layer) and packing of the non-polar tails 
(change in hydrophobic effect).  
All samples were stable under the test conditions. All the micelle 
formulations were stable at 4 °C and room temperature up to 100 days, and 
stable at 50 °C up to 30 days (Figure 4.19). The results indicate that the 
formulations possess long shelf-life and shipping stability. No precipitation, 










Figure 4.19 Concentration of schizandrol A in the aqueous solutions at 





4.2.6.2 Chemical stability of schizandrol A under UV exposure 
All samples are stable under the test conditions. In this study, there were 
no significant changes in the concentration of schizandrol A under 24 hours 
UV exposure. The results indicate that schizandrol A incorporated within the 
micelle did not undergo any photo-degradation after UV exposure up to 24 
hours.  
The locus of schizandrol A solubilization tends to be in the inner core or 
in the palisade layer of the micelle due to its hydrophobicity. The 
incorporation of schizandrol A into the micellar interior can prevent 
schizandrol A from external intrusion. Hence, the selected composition can be 
regarded as a suitable system for schizandrol A with regard to photostability of 
the cosmeceutical product. 
 






4.3 Pseudo-ternary Phase Diagrams 
The pseudo-ternary phase diagram (for example Figure 4.21) is drawn 
with the top apex representing the emulsifier system with Sm denoting a 
specific surfactant to cosurfactant weight ratio. Based on the pseudo-ternary 
phase diagram, the microemulsion (single phase) zone can be plotted. With the 
help of phase diagram, the concentration range of oil and emulsifiers 
(surfactant/cosurfactant) can be determined for easy formation of 
nanoemulsion. 
When L1695 and PEG 400 were mixed at a 2:1 ratio, they produced a 
solid phase with both low and high oil content. Therefore, water titration 
method is not suitable for this system. The spontaneous curvature (H0) of the 
main surfactant, L1695 in this study, dictates the phase behavior and 
microstructure. According to the high HLB value (16) of L1695, L1695 is 
more likely to produce an oil-in-water emulsion, since the H0 of a L1695 
monolayer at the oil-water interface is positive. Cosurfactant is added to obtain 
transparent isotropic systems at low surfactant concentration. 
In the present diagrams, the phase boundary separates a clear single-phase 
(1Φ) microemulsion zone (ME) and a turbid two-phase (2Φ) coarse emulsion 
region. 
4.3.1 Effect of cosurfactants 
In the present study, the addition of cosurfactant to the L1695/ethyl 
butanoate based emulsion system is necessary. This is because L1695 cannot 
produce isotropic solutions in oil without a cosurfactant at room temperature 
due to its greater affinity for water and limited solubility in oil phase (Garti et 
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al., 1999; Kim et al., 2009b; Thevenin et al., 1996). The addition of 
cosurfactant influences the emulsification properties of L1695 and has a 
pronounced effect of the self-aggregation of L1695 at the interface. 
Cosurfactants can impact on the solubility of the sucrose head group in the 
aqueous phase, thus altering the effective HLB value. Moreover, the addition 
of cosurfactants provides flexibility of the interface and decreases the 
interfacial rigidity. 
The pseudo-ternary phase diagrams with L1695 and different 
cosurfactants at constant Sm ratios (1:1) are displayed in Figure 4.21. The 
transparent microemulsion (ME) zones (1ɸ) are presented in the phase 
diagrams. The rest of the region on the phase diagram represents the turbid 
coarse emulsions. With the addition of selected cosurfactants, all the proposed 
compositions can form a single phase region. The largest microemulsion zone 
was given by the L1695/Ethanol emulsifier system in this study obtaining the 




Figure 4.21 The pseudo-phase diagrams of [L1695/EtOH], [L1695/PG], 
[L1695/PEG 400] /ethyl butanoate/water systems at room temperature with 
the same weight ratio of surfactant to cosurfactant (Sm) at 1:1. 
 
The amphiphilic nature of cosurfactants enables them to interact with both 
L1695 and with ethyl butanoate. As a result, the cosurfactant molecules affect 
the packing of micelles, the curvature of the interface and surface free energy 
at the interface. The cosurfactant in the system increases the mobility of the 
hydrocarbon tail and allows greater penetration of oil molecules into this 
region. 
All the cosurfactants are compatible with the L1695/ethyl butanoate 
system, but their effectiveness on microemulsion formation is different. The 
microemulsion zone changed greatly from ethanol to PEG 400 as the 
cosurfactant in the system. Among the cosurfactants used in this study, ethanol 
performed the best in enlarging the microemulsion zone followed by 
propylene glycol. PEG 400 displayed limited capacity as a cosurfactant. The 
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results reveal that ethanol fluidizes the interface more effective than other 
cosurfactants at constant values of Sm. 
The efficiency of ethanol to facilitate emulsification process can be 
attributed to increased fluidity of the oil-water interface due to rapid 
distribution of ethanol molecules at the interface. Ethanol is an amphiphilic 
molecule that has a polar end (hydroxyl group) and a non-polar end (ethyl 
group). The non-polar part may demonstrate a hydrophobic effect and change 
the curvature of the interface. This allows the flexibility of the interfacial film 
to be sufficient enough to take up surfactant molecules required to form a 
microemulsion. Therefore, the combination of L1695 and ethanol leads to the 
increase of mutual solubilization and to the existence of a stable monophasic 
fluid. 
Ethanol is less polar than propylene glycol and PEG 400, thus it is better 
for reducing the mismatch with the solvent and facilitating the compression 
and stabilization of the interfacial layer. Ethanol and propylene glycol can 
increase the miscibility of aqueous phase and oil phase by partitioning 
between them. 
It was found that when the chain length was increased and a hydroxyl 
group was introduced from ethanol to propylene glycol, a considerable 
decrease in the microemulsion zone was observed. A limited microemulsion 
zone was obtained with PEG 400. Ideally, cosurfactant molecule, which has 
similar affinity to both continuous and dispersed phases, will migrate to the 
oil/water interface and form a mixed surfactant/cosurfactant layer. The low 
efficiency of PEG 400 can be explained by the long chain of PEG 400 that 
adversely increases the interfacial rigidity and promotes a lamellar structure. 
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This results in the inhibition of emulsification process of L1695 and restriction 
of diffusion. An increase in bulk viscosity due to introduction of PEG 400 also 
affects diffusion. This may be the reason why L1695 and PEG 400 mixed at 
2:1 cannot form a clear solution with ethyl butanoate. 
The properties of cosurfactant greatly influence the phase behavior. 
Addition of ethanol enabled the L1695 to solubilize high concentration of oil, 
regardless of its strong affinity for the water phase. Propylene glycol only 
affected the oil solubility in the water-rich region. In the oil-rich region, both 
propylene glycol and PEG 400 showed limited impact. 
This work suggests that cosurfactants help to facilitate the emulsification 
of surfactant, L1695, by affecting the interfacial tension and rigidity of the 
interface and the association of the surfactant at the interface. The nature of 
cosurfactant showed a strong influence on the shape and size of the 
monophasic region. These diagrams provide useful information on the 
concentration range of components where microemulsions can exist. 
4.3.2 Effect of surfactant to cosurfactant weight (Sm) ratios 
The surfactant to cosurfactant weight (Sm) ratio is an important factor that 
influences the phase behavior of the emulsion system. 
The effect of surfactant to cosurfactant weight ratio (Sm) on 
microemulsion formation was evaluated for the further optimization of the 
nanoemulsion system. The pseudo-ternary phase diagrams with various weight 
ratios of L1695 to ethanol, propylene glycol and PEG 400 at ambient 
temperature are presented in Figure 4.22, Figure 4.23 and Figure 4.24. 
Based on the previous study, when the cosurfactant is absent (Sm=1:0), 
L1695 cannot emulsify the ethyl butanoate/water system. This may be because 
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the great affinity of L1695 to water. L1695 cannot sufficiently reduce the oil-
water interfacial tension at high oil concentrations. As a result, a cosurfactant 
was added to enable L1695 emulsify the system. When the cosurfactant was 
added to L1695 in Sm ratio 1:2, 1:1 and 2:1, a clear solution of oil and 
emulsifiers can be formed. The formation of a microemulsion can be attributed 
to the fact that the addition of cosurfactant results in an increase in the fluidity 
of the interface and the entropy of the system. 
 
Figure 4.22 The pseudo-ternary phase diagram of [L1965/EtOH]/Ethyl 
butanoate/water system at room temperature with different weight ratio of 
surfactant to cosurfactant (Sm): 1:2, 1:1, 2:1. 
 
For ethanol as a cosurfactant, increasing L1695 amount in the emulsifier 
system did not affect the microemulsion zone significantly (Figure 4.22). In 
particular, when Sm ratio was 1:1 and 2:1, the boundaries are similar. This 
indicates that at these two specific compositions, the interfacial properties are 
similar in solubilizing and stabilizing oil phase. When the cosurfactant in the 
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emulsifier system is increased, there is a decrease in microemulsion zone. This 
indicates that although ethanol contributes to the interfacial properties, when it 
is in high concentration, it will alter the emulsification of L1695 and cause 
decrease in oil solubilization. This may be due to the fact that a high 
concentration of cosurfactant changes the solution environment significantly, 
which changes the packing of L1695 resulting in insufficient emulsification. 
 
Figure 4.23 The pseudo-ternary phase diagram of [L1965/PG]/Ethyl 
butanoate/water system at room temperature with different weight ratio of 
surfactant to cosurfactant (Sm): 1:2, 1:1, 2:1. 
 
In the case of propylene glycol as the cosurfactant, the increase in L1695 
concentration increased the microemulsion zone (Figure 4.23). This can be 
explained by the fact that with more L1695 present in the system, more oil can 
be solubilized because of emulsification effect provided by L1695. The result 
indicates that it is the L1695 that is mainly responsible for the emulsification 
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process and for solubilizing the oil phase while propylene glycol had no 
appreciable effect on oil solubilization. 
Interestingly, when L1695 and propylene glycol were mixed at 2:1, this 
composition performed better than the other two compositions for medium 
concentration of oils. This may be attributed to the interface property given by 
the composition that such condition is favorable for oil to be incorporated into 
the system. 
 
Figure 4.24 The pseudo-ternary phase diagram of [L1965/PEG 400]/Ethyl 
butanoate/water system at room temperature with different weight ratio of 
surfactant to cosurfactant (Sm): 1:2 and 1:1. 
 
As for PEG 400, there is only a small extension of microemulsion zone 
with increasing amount of L1695 in the emulsifier system (Figure 4.24). The 
phase diagrams illustrate that PEG 400 is not an efficient cosurfactant for 
L1695 based emulsion system. There is no obvious difference in the 
microemulsion zone between these two compositions. This may be attributed 
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to the limited capacity of PEG 400 to fluidize the interface due to its weak 
interaction and relatively high viscosity. 
As shown in Figure 4.22, Figure 4.23 and Figure 4.24, the Sm ratios 
have little effect on the existence of a microemulsion with high water content 
or high oil content especially with PEG 400 present. These phenomena 
indicate that at low emulsifier concentration, the presence of cosurfactant does 
not greatly affect the emulsification properties of L1695, whereas at high 
emulsifier concentration, the cosurfactant has a more pronounced effect on 
phase behavior. This can be attributed to the interfacial activity of the 
cosurfactant. 
In microemulsions, almost all the surfactant molecules are present at the 
interface driven by the hydrophobic effect of the non-polar tail, while the 
amount of cosurfactant adsorbed at the interface depends on dispersion 
entropy and interface curvature. It is likely that the cosurfactant does not 
intrude into the interface at low concentrations of L1695, where the presence 
of cosurfactant only alters the solution environment to favor L1695 
solubilization in the oil phase. When the concentration of L1695 increases, the 
cosurfactant molecules move to the interfacial layer and exhibit interfacial 
activity. The change in interfacial composition consequently influences the 
water or oil solubilization. The irregular shape of the [L1695/PG (2:1)]/ethyl 
butanoate/water diagram may result from the propylene glycol incorporation 
into polar parts of the interfacial layer causing an alternation in interface 
curvature. 
The present study assessed the effect of cosurfactant type at a constant Sm 
ratio and the effect of the concentration of cosurfactant according to the Sm 
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ratio on the size of the microemulsion region. Pseudo-ternary diagrams 
showed the evolution of microemulsion related to Sm in all selected systems. 
The resultant pseudo-ternary phase diagrams can serve as an indicator for 
nanoemulsion composition selection. 
The investigations clearly distinguished the ability of three types of 
cosurfactants to promote the emulsification of L1695. Both ethanol and 
propylene glycol benefit the formation of microemulsion and can serve as a 
cosurfactant for L1695. Ethanol as the most efficient cosurfactant produced 
the largest microemulsion zone. The larger the microemulsion zone, the 
greater the emulsification efficiency of the system. Moreover, it can be seen 
from the phase diagrams that extensive dilution of the formulation is possible 
in L1695/ethanol based systems compared to other compositions. Therefore, 
ethanol was selected as the cosurfactant for the L1695/ethyl butanoate based 
emulsion system. 
Based on the study of Sm ratios, cosurfactants used in the present work 
appeared only to contribute to the fluidization of the interface and a high 
concentration of cosurfactant showed a destabilizing effect that narrows the 
microemulsion zone. However, the difference in microemulsion zone caused 
by different Sm ratios is not very pronounced. It is often desirable to minimize 
the amount of surfactant used in the formulation due to economic, consumer 
compliance and safety concerns. A Sm ratio of 1:1 was therefore preferred to 
minimize the surfactant concentration whilst maintaining good emulsification 
properties. 
The largest microemulsion zone was obtained at L1695/ethanol in a 
weight ratio (Sm) of 1:1. It is possible to achieve desirable properties of 
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subsequent nanoemulsion development with formulative and physiological 
advantages by this optimum selected composition. L1695/propylene glycol 
(1:1) emulsifier system was selected as propylene glycol is more friendly than 
ethanol in terms of skin application. PEG 400 was also selected as a 
cosurfactant as it is known to increase permeation when incorporated into 
formulations and it is relatively tolerable. Hence, L1695/PG (1:1) and 
L1695/PEG 400 (1:1) emulsifier systems are studied in the subsequent work 
for comparisons as well. 
 
4.4 Preparation of Nanoemulsion 
A coarse emulsion is produced using a high shear mixer and is fed 
directly into the inlet of a high pressure homogenizer. The high pressure 
homogenizer provides intense disruptive forces that cause the larger droplets 
of the coarse emulsion passing through the valve to be broken down into 
smaller ones. The homogenizing pressure, number of homogenization passes 
and emulsifier concentration contribute to controlling the droplet size. In 
practice, to reduce the droplet size to the level required in a nanoemulsion, it is 
usually necessary to operate at extremely high pressure to ensure the intensity 
of disruptive forces. 
The droplet size and size distribution were measured by DLS and served 
as criteria for selection of parameters and composition because they are the 
most important physical properties of any nanoemulsion system. They not 
only characterize the nanoemulsion system but can serve as an indicator of the 
quality and stability of the nanoemulsion formulation (McClements and Rao, 
2011; Tadros et al., 2004). It is more convenient to represent the full particle 
 118 
 
size distribution (PSD) using a measure of the central tendency of the 
distribution (mean value) and a measure of the width of the distribution 
(standard deviation and polydispersity index). Parameters such as the amount 
of oil, the amount and type of emulsifiers greatly affect the HPH method. 
4.4.1 Impact of process parameters 
The mean droplet size is a critical parameter of the nanoemulsion 
formulation due to its direct influence on 1) formulation stability; 2) 
appearance of the formulation; 3) efficacy of delivery; and 4) packing and 
handling of the product. The overall particle size distribution (PSD) is another 
important factor as well as the mean droplet diameter. The PSD is an 
indication of product quality for many practical applications of nanoemulsions. 
The particle size distributions are represented by “intensity weighted 
distributions” due to the measuring principle that the contribution of each 
particle in the distribution relates to the intensity of light scattered by the 
particle. 
Therefore, both mean droplet size and PSD are the criteria by which to 
optimize the efficiency of the manufacturing processes. 
The model emulsion used to study the effects of the operating pressure 
and number of homogenization passes was 10 wt% ethyl butanoate oil-in-
water emulsion stabilized by 3% [L1695/ethanol (1:1)]. 
4.4.1.1 Operating homogenizing pressure 
The homogenizing pressure was controlled by adjusting the regulator 
knob at the pressure regulator, expanding or contracting the gap height and 
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monitoring the pressure loss at the homogenizing pressure gauge. The droplets 
break-up and form a finer emulsion at the gap outlet (Innings et al., 2011). 
A distinct decrease in droplet size was observed after high pressure 
homogenization using 100 and 150 MPa as the operating pressure. Moreover, 
a more efficient decrease in hydrodynamic diameter was observed with 
increasing homogenizing pressure from 100 to 150 MPa (Figure 4.25). 
However, an operating pressure at 200 MPa could not produce an optically 
clear emulsion after 50 passes indicating unfeasibility of nanoemulsion 
formation at given composition. Additionally, a narrower droplet size 
distribution was observed with increasing homogenizing pressure. The small 
bulge at particle size larger than 1000 nm may be caused by beam steering or 
















(C) 200 MPa 
Figure 4.25 Droplet size and polydispersity index of nanoemulsion 
formation by HPH method at different homogenizing pressure; and typical 
size distribution (by intensity) after 50 passes: (A) 100 MPa, (B) 150 MPa, (C) 
200 MPa. 
 
The decrease in droplet size with increased pressure can be attributed to 
the increase in the intensity of turbulence forces generated in the 
homogenization dispersing chamber. The turbulence forces are regarded as the 
main contribution to the break-up of the dispersed phase into small droplets as 
well as laminar shear and cavitation (Walstra and Smulders, 1998; Floury et. 
al., 2004; Hakansson 2009). Turbulence intensity increases strongly with 
increasing homogenizing pressure. An intense turbulent and shear flow field 
converted from the energy input leads to the fragmentation of the coarse 
emulsion. The efficiency of the HPH process depends on the relative motion 
between the droplets and on collision and coalescence. 
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The droplet size of the end product is the result of equilibrium between 
droplet break-up and re-coalescence. Deformation is the critical step in droplet 
disruption and is induced by shear forces. Though there may be many physical 
processes contribute to droplet disruption such as turbulence, pressure drop, 
and cavitation, the efficiency of disruption mechanisms is overall determined 
by the operating pressure (Walstra and Smulders, 1998). At low pressure, the 
homogenizer may be incapable of generating sufficiently intense disruptive 
forces. At too high pressure, a small droplet size nanoemulsion cannot be 
achieved because the emulsifiers cannot be adsorbed quickly enough at the 
interface to prevent re-coalescence. Without the emulsifiers adsorbing onto the 
created interface, an increase in droplet size due to re-coalescence and 
flocculation will occur. The extent of recoalescence correlates to the 
homogenizing pressure, emulsion composition and flow pattern (McClements 
1999; Tesch and Schubert 2002; Floury et al. 2004). When the operating 
pressure is 200 MPa, an optically clear nanoemulsion cannot be produced after 
50 passes. This can be explained by; when operating at extremely high 
pressure, there is more likelihood that retardation of droplet breakup and 
significant re-coalescence can take place due to insufficient stabilization. 
4.4.1.2 Number of homogenization passes 
For each operating pressure applied, the droplet size produced by the 
HPH method decreased as the number of passes increased. The number of 
homogenization passes corresponds to the energy spent in generating 
nanoemulsions. More passes means more energy input. More passes provide 
increased process time thus enhance absorption of emulsifiers and more 
chance for the emulsion droplets to undergo intensive disruptive forces to be 
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successfully disrupted. It is necessary for emulsion droplets to have a longer 
residence time within the disruption zone than their deformation time. 
The effects of the number of homogenization passes on nanoemulsion 
formation are presented in Figure 4.26. The homogenization efficiency 
became lower after 30 passes at 150 MPa in the case of 10 wt% oil in the 
coarse emulsion. The change in PSD of the model emulsion was therefore 
determined by the number of homogenization passes for the model emulsion 
sample processed by HPH method at 150 MPa (Figure 4.27). 
 
Figure 4.26 Effect of number of homogenization passes on the average 
droplet diameter produced in 3% L1695/ethanol (1:1) ethyl butanoate-in-water 






Figure 4.27 Evolution of particle size distribution (PSD) related to number 
of homogenization passes. The model emulsion consisted of 3% 
[L1695/ethanol (1:1)]/10% ethyl butanoate/87% water. 
 
At fixed operating pressure of 150 MPa, 50 homogenization passes 
provide optically clear nanoemulsions without over-processing phenomena. 
The large droplet size and broad size range of the coarse emulsion was 
expected based on the phase diagram study. The change in PSD is attributed to 
the energy input. For efficient and uniform homogenization it is important to 
ensure the energy input overcomes the Laplace pressure. The overall shape 
change of the sample starts after 30 passes. In addition, the width and breadth 
of the distribution becomes narrower afterwards. 
Although there is no significant decrease in droplet size after 40 passes, 
50 homogenization passes ensure the formation of nanoemulsion within the 
nano-sized range providing a narrower droplet size distribution. Furthermore, 
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there is no increase in droplet size caused by predominating re-coalescence 
phenomena over droplet disruption after 50 homogenization passes. 
The data show that it is advantageous to use higher homogenizing 
pressures (150 MPa) and a larger number of homogenization passes (50 passes) 
to obtain small droplets with a narrow particle size distribution. 
4.4.2 Impact of formulation variables 
4.4.2.1 Concentration of oil phase 
Oil is a crucial component in nanoemulsion that solubilizes the 
hydrophobic ingredients and controls the physicochemical properties of the 
formulation namely, density, viscosity, interfacial tension and phase behavior 
(McClements and Rao, 2011; Wooster et al., 2008). The amount of oil used in 
formulations for medical applications is generally within 5-20 wt% 
(Tamilvanan, 2008). With an increasing amount of oil in the system, the 
breakup of droplets becomes more difficult for HPH methods. The time for 
droplets to become deformed within the disruption zone of a homogenizer 
increases consequently. Concentration of ethyl butanoate at 10, 15, and 20 wt% 
was selected to prepare nanoemulsion under the same condition (with 3% 
L1695/ethanol (1:1), 50 homogenization passes under 150 MPa) so as to 
investigate the influence of oil concentration on nanoemulsion formation. 
The results revealed that the concentration of oil greatly influenced the 
efficiency of nanoemulsion formation and droplet size produced as shown in 
Figure 4.28. After 50 homogenization passes, a clear nanoemulsion can be 
obtained with 10 and 15 wt% of ethyl butanoate with a mean droplet size in 
the nano range. With regard to droplet size distribution, PDI value was 
obviously improved with 10 wt% ethyl butanoate compared to 15 wt%. The 
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efficiency of nanoemulsion formation decreased with increasing oil amount, 
i.e. 40 passes for 10% oil, 50 passes for 15% oil, and when concentration of 
ethyl butanoate is as high as 20%, 50 homogenization passes cannot ensure 
formation of a nanoemulsion at 150 MPa operating pressure (Table 4.9). The 
results suggested that the breakup of droplets became less efficient with an 
increasing amount of oil in the system under such condition. This may be 
caused by the increase in oil content reduced the availability of fixed amount 
emulsifiers to be efficiently adsorbed onto the newly formed droplets, lower 
the interfacial tension and stabilize the system. This opposes droplet disruption 
and thus requires an increase in energy consumption. Moreover, increasing 
concentration of oil increase the collision rate between droplets and promotes 
the flocculation rate as well as coalescence rate which result in a droplet size 
increase (Soleimanpour et al., 2013). The flocculation is encouraged when 
droplets are close together. Tests on nanoemulsion formation with 20 wt% 
ethyl butanoate showed that at least 60 homogenization passes are necessary 
to prepare optically transparent nanoemulsion. 
After HPH process, optically clear 15 wt% ethyl butanoate oil-in-water 
nanoemulsion can be produced. However, the PDI value was close to 0.5 
indicating a broad size distribution. A poly-disperse system with a broad size 
distribution is thermodynamically unstable. Larger droplets have a lower 
surface-to-volume ratio thus a lower energy state that they are more 
energetically stable than smaller ones. The poly-dispersity in droplet size 
greatly favors the coalescence of the droplets that droplets join together 
making a greater volume droplet with smaller interfacial area to release the 
free energy. This will lead to phase separation where all droplets coalesce to 
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form two separated phases. The poly-dispersity in droplet size also promotes 
the Ostwald ripening where small droplets shrink and larger droplets grow, 
driven by the concentration gradient of oil molecules (Taylor, 1998). As a 
result, there is a higher tendency for poly-disperse system to break-down than 
for mono-disperse system. Destabilization phenomenon such as phase 
separation, creaming or sedimentation is predictable. A monodisperse system 
has a much lower tendency to break-down than a polydisperse system, and 10 
wt% ethyl butanoate was therefore selected for the subsequent nanoemulsion 
formulation. 
Table 4.9 Mean droplet size and polydispersity index of emulsions 























Figure 4.28 Effect of oil concentration on nanoemulsion formation by HPH 
at 150 MPa. The resultant samples in vials are placed in the order of original 
coarse emulsion, sample after 10, 20, 30, 40 and 50 passes (from left to right). 
 
4.4.2.2 Concentration of emulsifiers 
The emulsifier is the most important component to form nanoemulsion 
which controls rate of adsorption and coalescence by modifying the interface 
(McClements and Rao, 2011). The concentration, rate of collision and activity 




During the HPH process, the surfactant molecules adsorb onto the newly 
formed oil-water interface, reducing the surface tension, facilitating the 
droplet disruption, and restricting the coalescence and aggregation of emulsion 
droplets (Guzey and McClements, 2006; McClements et al., 2007). The 
adsorption kinetics of the emulsifier has a significant effect on the size and 
size distribution of the droplets. Consequently, the type and concentration of 
surfactant play a vital role in this process by influencing the adsorption 
kinetics and dynamic interfacial tension. 
For a nanoemulsion formulation, 5-10% emulsifiers are usually required 
to stabilize the emulsion system (Tamilvanan, 2008). In the present study, 3, 5 
and 7 wt% emulsifiers (L1695/ethanol, 1:1) were used to investigate the 
influence on nanoemulsion formation.  
All the formulations containing different amount of emulsifiers presented 
a transparent appearance with droplet size in the nano range after 50 
homogenization passes. There is no significant difference (p>0.05) in droplet 
size of the end product when the concentration of emulsifiers was increased 
from 3 to 7 wt% in the system (Table 4.10). In general, the droplet size 
produced tends to decrease with increasing emulsifier concentration. However, 
when a critical diameter has been reached, the distribution becomes narrower 
rather than further fragmentation of droplets (Håkansson et al., 2009; Soon et 
al., 2001). The degree of size reduction from the coarse emulsion to final 
fabricated nanoemulsion (the minimum stable droplet size that can be 
produced by HPH method) is not dependent on the amount of the emulsifier 
present in the system. This phenomenon can be explained by the role the 
emulsifier plays in droplet break-up. The emulsifier facilitates droplet break-
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up by decreasing the surface and interfacial tension. It is known that the lower 
the interfacial tension, the easier the drop breaking, and smaller the drop size 
that actually forms (Sjoblom, 2010). This is hence related to an important 
property of surfactants, surfactant effectiveness, which is defined as the 
maximum reduction of the interfacial tension a surfactant can produce, 
regardless of amount used (Rekvig et al., 2003; Rosen and Kunjappu, 
2012).This suggests that the ability of emulsifiers to facilitate the droplet 
break-up is limited by the type of surfactant present in the system. 
In addition, the results show that the number of homogenization passes 
required, which correspond to the efficiency of emulsifiers on nanoemulsion 
formation, decreased as the concentration of emulsifiers increased (Figure 
4.29). This trend is expected because the more emulsifier present in the system, 
the more rapidly the newly formed droplet surface can be covered. The 
sufficient emulsifiers in the system are critical for effective steric stabilization, 
preventing the droplets from flocculating and coagulating. 
Table 4.10 Mean droplet size and polydispersity index of emulsions 
containing different emulsifiers (L1695/ethanol, Sm=1:1) amount after 50 
homogenization passes at 150 MPa. 
Emulsifiers conc. 
(wt%) 
Hydrodynamic diameter Polydispersity index 














Figure 4.29 Effect of emulsifier concentration (wt%) on the mean droplet 
size and polydispersity index (PDI) of nanoemulsion formation using HPH 
method at 150 MPa. The resultant samples in vials are placed in the order of 
original coarse emulsion, sample after 10, 20, 30, 40 and 50 passes (from left 
to right). 
 
Moreover, in practice, it is desirable to use as low concentration of 
emulsifier as possible to produce consumer friendly products. In this study, 3 
wt% of emulsifiers is sufficient to enable the freshly created surface area 
developed by droplet break-up to be coated rapidly during the emulsification 
process. 3 wt% of emulsifiers is therefore selected for subsequent 




4.4.2.3 Composition of emulsifiers 
Effect of cosurfactant type. A cosurfactant that influences the 
formation of the microemulsion zone is expected to have an impact on the 
nanoemulsion formation process as well. A cosurfactant present in the coarse 
emulsion may have an impact on the nanoemulsion formation process by 
affecting the effectiveness of the surfactant due to its interaction with the 
surfactant monolayer which impacts on the packing, interfacial curvature and 
interfacial energy (Azeem et al., 2009b). In this study, three kinds of 
cosurfactants were examined on the homogenization process. Cosurfactants 
selected in this study can improve the solubility of schizandrol A in the 
aqueous phase and they have been reported to have skin permeation-enhancing 
effects.  
With regard to the nanoemulsion formation using the HPH method, the 
formation process of nanoemulsion appeared to be similar (Figure 4.30).  
Transparent nanoemulsions were obtained after 40 passes and the droplet size 
was finally stabilized at the range of 10-15 nm (p>0.05) in all the 
homogenization processes. This can be attributed to that L1695 as the main 
surfactant was responsible for the emulsification in nanoemulsion formation. 
The type of cosurfactant did not greatly affect the stabilization of the interface 
as studied in phase diagrams and thus the nano-sized droplet formation. This 
may be also due to the low concentration of emulsifiers employed in the study, 
















Figure 4.30 Effect of cosurfactant type on L1695-based ethyl butanoate-in-
water nanoemulsion formation: (A) ethanol, (B) propylene glycol, (C) PEG 
400. The resultant samples in vials are placed in the order of original coarse 
emulsion, sample after 10, 20, 30, 40 and 50 passes (from left to right). 
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Table 4.11 Mean droplet size and polydispersity index of emulsions 
containing different cosurfactant (3% [L1695/CoS], Sm=1:1) after 50 











Propylene glycol 12.46±1.190 
 
0.340±0.066 




Surfactant to cosurfactant (Sm) ratios. The presence of cosurfactant 
helps to reduce the amount of surfactant in the system. The Sm ratios have 
been evaluated by the size of microemulsion zone that they can achieve. The 
larger the area, the greater the emulsification efficiency of the system. Study 
on phase diagrams illustrated that Sm ratio did not affect the microemulsion 
zone at high water content to a large extent. A similar result was obtained in 
the formation of the nanoemulsion (Table 4.12). The decrease in droplet size 
when the L1695 concentration was increased can be attributed to the fact that 
there are more emulsifiers present in the system to facilitate droplet disruption. 
Table 4.12 Mean droplet size and polydispersity index of emulsions 
containing different surfactant to cosurfactant (3% [L1695/ethanol]) weight 






















Figure 4.31 Effect of surfactant to cosurfactant weight ratio (Sm) on the 
average droplet size and PDI value. The resultant samples in vials are placed 
in the order of original coarse emulsion, sample after 10, 20, 30, 40 and 50 
passes (from left to right). 
 
Based on these findings, the formulation composed of ethyl butanoate, 
L1695/ethanol (1:1) and water; ethyl butanoate, L1695/propylene glycol (1:1) 
and water; ethyl butanoate, L1695/PEG 400 (1:1) and water at the weight ratio 
of 10/1.5/1.5/87 were selected to produce and optimal nanoemulsion to 
incorporate schizandrol A at an operating pressure of 150 MPa and 50 passes 
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(Table 4.13). A control group of experiments pure water with 2 mg/ml 
schizandrol was also investigated. 










(mg/ml) Type (Sm=1:1) 
Conc. 
(wt%) 
NE1 L1695/EtOH 3 10 87 2 
NE2 L1695/PG 3 10 87 2 
NE3 L1695/PEG 400  3 10 87 2 
 
 
4.5 Characterization of Nanoemulsion Containing Schizandrol A 
4.5.1 Droplet size and polydispersity index 
The droplet size in the nanoemulsion formulation containing schizandrol 
A was about the same size range compared to those without schizandrol A 
(blank formulations). The homogenization process appeared to be similar to 
the blank formulations. The results show that schizandrol A did not have much 
effect on the HPH process or the physical quality of the end product (Table 
4.14). 
The control group consisting of pure water and schizandrol A was cloudy 
throughout the experiment (Figure 4.32 (D)). The phase separation (before 
HPH process) implies the thermodynamic instability of the system that the 
free energy of separated solid and water phase is lower than that schizandrol A 
dispersed (suspended) in water phase. The non-spontaneous dispersion process 
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requires energy input to produce small particles from large ones. Although a 
decrease in droplet size was obtained by DLS analysis after HPH process (150 
MPa, 50 passes), the sample showed phase separation throughout the process. 
This is because there was no stabilization mechanism present during HPH 
process. The small particles aggregated or coalesced to reduce the total surface 
energy of the system. Both Brownian motion and hydrodynamic motions lead 
to collisions of particles resulting in aggregation. 
After HPH process, proposed formulations can produce optically clear 
nanoemulsion containing schizandrol A (Figure 4.32 (A), (B) and (C)). This is 
attributed to the incorporation of L1695-based emulsifiers that enables the 
system to overcome the aggregation or coalescence process by providing 
repulsive mechanism during HPH process. The accumulation of emulsifiers at 
the interfacial layers introduces steric repulsion between particles. This strong 
repulsion counterbalances the attractive van der Waals forces and stabilizes 
the system. The adsorption of emulsifiers releases the free energy by lowering 
the surface and interfacial tension and henceforth stabilizes the system. As a 
result, transparent nanoemulsions containing schizandrol A were achieved. 
Table 4.14 Droplet size and PDI value of the developed nanoemulsion 




















































Figure 4.32 Preparation of L1695-based ethyl butanoate oil-in-water 
nanoemulsion containing 2 mg/ml schizandrol A: (A) NE1, (B) NE2, (C) NE3, 
(D) control samples consisting of 2 mg/ml schizandrol A in ultra-pure water. 
The resultant samples in vials are placed in the order of original coarse 






Figure 4.33 Particle size distributions of samples containing 2 mg/ml 
schizandrol A after 50 homogenization passes at 150 MPa. 
 
4.5.2 Microstructure study 
The nanoemulsion formulation samples were examined by electron 
microscopy to study the particle shape and verify the droplet size determined 
by light scattering analysis. The shape of particles may have a significant 
impact on the performance of the formulation. Moreover, the study of droplet 
shape provides a check on the validity of the size measurement and data 
analysis which assume spherical droplets. 
The TEM and cryo-FESEM micrographs of the nanoemulsion 
formulations were shown in Figure 4.34 and Figure 4.35 to illustrate their 
microstructure. These structures were considered to be o/w nanoemulsions 
because they have been formed at high water content (87 wt% water). This is 
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supported by the results from electrical conductivity measurement. From the 
Figure 4.34 displayed, the microstructures observed are discrete spherical 
droplets. All of the different compositions of nanoemulsion formulation show 
similar structures. In the TEM micrographs, the droplets were highly uniform 
with an average droplet diameter smaller than 20 nm. These diameters of 
droplet observed in TEM are in good accordance with the hydrodynamic 
diameter values measured by DLS. The cryo-SEM micrographs also 









Figure 4.34 TEM images of nanoemulsions containing schizandrol A: (A) 












Figure 4.35 Cryo-FESEM images of nanoemulsions containing schizandrol 
A: (A) NE1, (B) NE2, (C), NE3. The length of scale bar is 100 nm. 
 
4.5.3 Physicochemical properties of nanoemulsion formulation 
The measurements of the physicochemical properties of the formulations 
provide information for a better understanding of the product with regard to 
practical application. 
The electrical conductivity, pH and refractive index of the nanoemulsion 
formulation were measured to understand the physicochemical properties of 
the product (Table 4.15). The electrical conductivity gives the indication of 
the nanoemulsion structure. Based on the result, prepared nanoemulsions were 
oil-in-water nanoemulsions which water is the continuous phase while the oil 
phase is the disperse phase. The pH measurement of the nanoemulsion 
formulations provides information on the feasibility of the practical 
application. For topical applications, a pH lower The pH values of the 
nanoemulsion formulations at the range 4.5-5.5 which is friendly to the skin  
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indicating they are suitable for topical application (Lambers et al., 2006; 
Schreml et al., 2010). The dynamic viscosity of the nanoemulsion 
formulations was around 1.1 mPa∙S close to that of water (0.89 mPa∙S). The 
refractive index is related to the aesthetic concerns, indicating how the 
emulsion will look to the consumer. The refractive index of the nanoemulsion 
formulations was found around 1.338 which is also close to the value of water 
(1.333) indicating the oil-in-water structures. The encapsulation efficiency 
results demonstrated that approximately 60% of the total schizandrol A 
content was found in the inner phase of the nanoemulsions. There is no 
significant difference (p>0.5) in encapsulation efficiencies in the purposed 
formulations. The results suggest that some of schizandrol A molecules might 
be located in the surface layer of emulsion droplets (or the interface layer) due 
to interaction of schizandrol A molecule with L1695 and/or cosurfactant 
molecules. 
Table 4.15 Physicochemical properties and encapsulation efficiencies of 













(σ, µs/cm) (mPa∙S) (%) 
NE1 58.96±9.34 5.07±0.51 1.020±0.008 1.337 64.77±8.50 
NE2 51.75±2.26 4.86±0.26 1.143±0.024 1.338 60.81±8.07 






4.5.4 Stability studies 
Oil-in-water nanoemulsion is a heterogeneous dispersion of oil in water 
that it will be subjected to various instability processes such as aggregation, 
flocculation, coalescence, Ostwald ripening finally resulting in phase 
separation. However, the proper selection of oil phase and emulsifiers can 
improve the physical stability of a nanoemulsion (Tamilvanan, 2008). The 
droplet size and polydispersity index are important representative parameters 
in the control of nanoemulsion stability and were used to evaluate the physical 
stability of the formulation in this study. 
The effect of temperature on stability of the nanoemulsion formulated 
with the proposed emulsifier systems was illustrated in Figure 4.36. The 
temperature is an important variable that may induce a change in the 
emulsifier interfacial properties and lead to phase inversion. As seen in Figure 
4.36, small droplet size with dH in the range of 12-15 nm (NE1), 11-13 nm 
(NE2), 12-13 nm (NE3) indicates the nano droplet size is retained across the 
temperature range studied (5 °C to 60 °C) in the formulation and PDI value of 
0.25-0.38 (NE1), 0.21-0.31 (NE2), 0.21-0.31 (NE3) indicates the mono-
dispersed o/w nanoemulsion formation remains monodispersed. Each 
formulation was prepared in triplicate and the measurement for each sample at 
the given temperature was repeated at least 5 times. 
The PDI is a measure of particle homogeneity and varies from 0 to 1 and 
PDI value below 0.5 is an indication for a homogeneous system. The results 
show that the droplet size and PDI value were not significantly affected by the 
temperature change. The fluctuation in droplet size in NE1 sample at relatively 
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high temperature (>40 °C) may because the change in mobility and 









Figure 4.36 Droplet size and polydispersity index as a function of 
temperature for the nanoemulsion formulation containing schizandrol A: (A) 
NE1, (B) NE2, (C) NE3. 
 
The physical stability of the prepared nanoemulsion formulations was 
monitored over time and the evolution of droplet size during the storage time 
is represented in Figure 4.37. The droplet size remains within the 10-15 nm 
range for all samples at least up to 30 days storage. These indicate there were 












Figure 4.37 Droplet size and polydispersity index as a function of storage 
time of the nanoemulsion containing schizandrol A: (A) NE1, (B) NE2, (C) 
NE3. 
 
The stability of nanoemulsion formulations containing schizandrol A 
against destabilization phenomena such as coalescence and Ostwald ripening 
was ascertained by droplet size and size distribution measurement. 
Destabilization phenomena such as creaming, sedimentation, and flocculation 
were not observed. 
The apparent rate of coalescence largely follows the first-order kinetics 
(Nt= N0 e
−Kct
) where N0 and Nt are the numbers of droplets per unit volume of 
emulsion initially and time (t), respectively, and Kc is the rate of droplets 
coalescence which can be determined by plotting 3*ln(Dt/D0) against time (t) 




lnDt = lnD0 + 
   
 
 (Equation 4.6) 
where D0 and Dt are the average droplet sizes initially and at time (t), 
respectively. The results shown in Figure 4.38 indicate no coalescence was 
achieved by the proposed composition of nanoemulsion. 
 
Figure 4.38 Coalescence kinetics of schizandrol A loaded nanoemulsions at 
room temperature. The 3*ln(Dt/D0) is plotted against storage time (hour). 
 
The increase in mean droplet size as a function of time following a linear 
law (dH
3
-t) (the Lifshitz-Slesov-Wagner, LSW theory) as an indication of 
Ostwald ripening process was not found in this study as shown in Figure 4.39, 





Figure 4.39 Ostwald ripening kinetics of schizandrol A loaded 





) is plotted against storage time (hour). 
 
As seen in Figure 4.40, schizandrol A in selected nanoemulsion 












Figure 4.38 Concentration of schizandrol A in the nanoemulsion 
formulations as a function of storage time: (A) NE1, (B) NE2, (C) NE3. 
 
Stress testing such as centrifugation, heating-cooling cycles and freeze-
thaw cycles were conducted to exclude the possibility of physically unstable 
formulations. No sedimentation, phase separation, turbidity or creaming was 
observed in all the selected formulations after centrifugation, the heating-
cooling cycles and freezing/thawing process. Developed formulations 
displayed reversible freeze/thaw cycles indicating good stability to freezing. 
The good stability of nanoemulsions obtained is in good accordance with 
the previous report that the droplet size affects the stability of a nanoemulsion, 
the small droplet size presented better stability (Solans et al., 2005). The 
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results also demonstrate the effectiveness of sucrose laurate emulsifiers to 
stabilize the droplets. 
The proposed nanoemulsion formulations did not display any phase 
separation, turbidity, creaming or cracking after centrifugation or after the 
heating-cooling cycles and freezing/thawing process. All samples were found 
to be stable and the stress testing confers a long shelf life to the developed 
nanoemulsion. 
 
4.6 In Vitro Permeation Studies 
The permeability of schizandrol A of three nanoemulsion formulations 
containing the same amount of schizandrol A but with different cosurfactants 
was investigated and compared to a control formulation consisting of 
ethanol/water (50/50, w/w) containing the same amount of schizandrol A. 
The in vitro permeation of schizandrol A through a synthetic membrane 
was determined in the receptor fluid in a Franz diffusion cell over a 24-hour 
time period using HPLC. The amount of schizandrol A penetrated per unit 
area (mg/cm
2




Figure 4.39 In vitro penetration profiles of cumulative permeated 
schizandrol A amount per area obtained for 24 hours by the Franz cell 
diffusion test using synthetic membrane. 
 
From Figure 4.41, it can be seen the combination of L1695 with 
propylene glycol exhibited the best penetration profile. Compared to the 
control group, all the formulations encourage the schizandrol A penetrating 
through the synthetic membrane. From the 0 to 4 hours, the penetration is 
promoted to a greater degree after that the penetration gradually reaches the 
plateau. 
Optimally, the testing of transdermal delivery systems should be 
performed in vivo. However, this is often impossible in the developmental 
stages due to the complexation of in vivo protocols. In vitro assessment has 
become increasingly important to investigate the potential usefulness of the 
formulation. The Franz diffusion cell is widely used to assess skin 
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permeability, study the relationship among active ingredient, formulation and 
skin and has become the in vitro method of choice in the industry. 
Although human tissue is the most appropriate medium to use in the 
diffusion cell method, there are many problems such as limited availability, 
legal issues and particularly variance between specimens from different sites, 
subjects, gender, race, age and skin condition (Haigh and Smith, 1994). Given 
the fact that the skin of experimental animals differs markedly from human 
skin in features and animal testing is discouraged for cosmetic products and 
their ingredients, , a number of synthetic membranes has been used to predict 
percutaneous absorption in vivo due to its commercial availability, stability, 
interbatch uniformity and ease of usage. The synthetic membranes are 
employed in Franz diffusion cell studies intended for simulation of the skin 
and quality control. A polysulfone membrane was selected in this study. The 
membrane was subjected to a pre-soaking procedure in order to ensure 
uniform performance across all tests and time. 
The penetration of schizandrol A through the synthetic membrane can be 
considered as a partition-diffusion process. All the nanoemulsion formulations 
exhibited good capacity to transport schizandrol A across the synthetic 
membrane. This can be attributed to the several features of nanoemulsion. The 
concentration gradient generated between the formulation and the membrane 
facilitated the diffusion. The small droplet size close contacted to the 
membrane that a high concentration of oil could penetrate. The small droplet 
size will also make it possible that the droplet containing schizandrol A 
directly penetrates through the stratum corneum without nanoemulsion fusion 
to the skin surface. Moreover, the cosurfactants in the system played an 
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important role in transdermal delivery for L1695-based ethyl butanoate/water 
nanoemulsion formulations. 
All the cosurfactant used can be regarded as a permeation enhancer. 
Ethanol has been used to enhance the flux of many drugs through the skin and 
the effect has been found to be concentration dependent. However, a high 
level of ethanol will cause dehydration of the skin and reduce permeation. 
Propylene glycol is a well-known humectant that helps skin to maintain 
moisture and is low cost. Propylene glycol has been used successfully to 
enhance active substance penetration across the skin. PEG 400 can act as a 
penetration enhancer due to its interaction with lipophilic compounds. The 
different extend of the cosurfactant influencing the permeation depends on its 
ability to disturb or fluidize the lipid structure of the stratum corneum (Benson, 
2005; Williams and Barry, 2012). 
The propylene glycol formulation (NE2) performs slight better than the 
others possibly due to the fact that it extracts the lipids from the membrane 
more efficiently than ethanol and PEG 400. After 6 hours, propylene glycol 
and ethanol (NE2 and NE1) provide similar penetration capacity. The 
permeation of schizandrol A in the designated nanoemulsion formulations was 
attributed to the molecular orientation within the lipid layer. 
From the above results it can be seen that the nanoemulsion formulations 
proposed are stable, have a good shelf life and are effective in delivering 





CHAPTER 5 CONCLUSIONS 
 
Nanoemulsions of schizandrol A have been successfully formulated by 
high pressure homogenization using GRAS materials. 
We have shown that sucrose laurate (L1695) is the best surfactant to 
solubilize schizandrol A among the non-ionic surfactants investigated. Ethyl 
butanoate is the most effective oil phase to dissolve schizandrol A compared 
to the oils tested. Ethanol was found to be the most suitable cosurfactant for 
the L1695/ethyl butanoate based emulsion. The optimal surfactant-to-
cosurfactant weight ratio is 1:1 for the emulsifier system. The optimal 
operating pressure for the HPH method is 150 MPa. 40 passes through the 
homogenizer are necessary to form a stable emulsion of small droplet size 
with a narrow size distribution. The droplet size of nanoemulsion formulation 
obtained is approximately 10-15 nm with a polydispersity index about 0.3. 
The nanoemulsions created are stable for 30 days and at a temperature up to 
60 °C. The nanoemulsions containing schizandrol A displayed excellent 
physical and chemical stability. The results from permeation studies of 
nanoemulsion formulations containing schizandrol A point to its promising 
application of the formulation for transdermal delivery. 
Based on our studies, it was apparent that the solubility of schizandrol A 
in the aqueous phase is dependent on the solubilizing agents and their 
concentration. The non-ionic surfactant L1695 with a sucrose head group 
performed better than Tweens which have a polyoxyethylene head group. The 
polarity of the cosolvent affects the solubilization of schizandrol A. However, 
the addition of cosolvent did not show pronounced improvement on the 
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solubility of schizandrol A. Cyclodextrins and their derivatives contributed 
only marginally to the enhancement of schizandrol A solubility probably due 
to steric hindrance. The combined use of solubilizing agents promoted the 
solubilization of schizandrol A with the most notable effect from using mixed 
micelles. The solubility in oils is related to the molecular volume of oils. Oils 
with low molecular volume tend to solubilize a larger amount of schizandrol A. 
The type and concentration of cosurfactants were investigated to find the 
most suitable cosurfactant for nanoemulsion formulation because it is difficult 
to form a microemulsion with L1695 alone. The presence of the cosurfactant 
greatly affects the phase behaviour of the emulsion system. The existence of a 
single-phase microemulsion zone was illustrated by the pseudo-ternary phase 
diagrams. All of the selected blends of cosurfactant and L1695 can form a 
single-phase microemulsion. The addition of cosurfactant can reduce the 
interfacial rigidity of the condensed L1695 film and destabilize the lamellar 
phase (liquid crystal structure). It was shown that the type of the cosurfactant 
strongly influences the shape and the extent of the microemulsion zone. 
Ethanol as the cosurfactant greatly promotes the formation of microemulsion 
zone. The surfactant to cosurfactant weight ratio (Sm) has little effect on the 
microemulsion formation at both high and low water content. The phase study 
reveals that the maximum amount of oil could be incorporated when the 
surfactant to cosurfactant ratio Sm was 1:1. 
Process parameters were determined by using a model composition 
consisting of 3 wt% [L1695/ethanol (1:1)], 10 wt% ethyl butanoate and 87 wt% 
water. In order to achieve minimum stable droplet size, the operating pressure 
must be high enough to generate sufficient pressure gradient to disrupt the 
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droplets of the coarse emulsion. Sufficient time (number of homogenization 
passes) should be taken for these droplets to be completely disrupted within 
the homogenization zone to be completely disrupted. The high operating 
pressure (150 MPa) produced a small droplet size in the emulsion with a 
narrow droplet size distribution. However, a clear emulsion cannot be obtained 
at a higher pressure (200 MPa) due to the coalescence. Therefore, the 
operating pressure of the HPH affects the deformation and break-up of the 
disperse phase droplets. The number of homogenization passes is another 
important process parameter which affects the total energy input for droplet 
disruption. The results show that the droplet size and size distribution of the 
nanoemulsion did not change significantly after 40 passes. 
The efficiency of homogenization depends on the type and amount of 
emulsifier present and the concentration of oil in the system. All these 
formulation variables were optimized to produce nanoemulsions with 
minimum droplet size. The oil droplets obtained in the present work were 
approximately 15-20 nm by the HPH method at 150 MPa with 10 or 15 wt% 
ethyl butanoate, 3 wt% L1695-based emulsifiers after 50 homogenization 
passes. A nanoemulsion could not be obtained in this study when ethyl 
butanoate exceeded 20 wt% in the system. The more oil in the system the 
more energy or more emulsifier required to disrupt the droplets. The study of 
emulsifier concentration on the nanoemulsion formation reveals that the 
amount of emulsifier affects the efficiency of the nanoemulsion formation. 
However, the impact on droplet size is negligible. 
Schizandrol A was incorporated into the designated nanoemulsion 
formulation systems. The average droplet size and polydispersity index of 
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obtained nanoemulsions were analyzed by DLS. The schizandrol A loaded 
nanoemulsions have a droplet size ranging from 10 to 20 nm with a PDI of 
0.2~0.3. The microstructure was studied by TEM and cryo-SEM observations 
further validating that the emulsion droplets produced are in nano size range. 
Both microstructure and electrical conductivity revealed the oil-in-water 
structure of the formulation. The pH of proposed formulations is friendly to 
skin and other physicochemical properties of the formulations such as 
viscosity and refractive index were similar to water. Encapsulation efficiencies 
for proposed formulations demonstrated about 60% schizandrol A presented in 
the oil droplets. 
A series of stability tests were conducted. Coalescence and Ostwald 
ripening was not observed with a water concentration up to 87 wt% during 
storage. Destabilization phenomena such as creaming, sedimentation, and 
flocculation were not observed. The concentration of schizandrol A in the 
formulation remained approximately constant for 30 days which suggests that 
there is no chemical degradation. The droplet size is stable up to 60 °C. 
Centrifugation, heating-cooling cycles and freeze-thaw process did not 
introduce any phase change in the nanoemulsion formulations. These indicate 
that the formulated nanoemulsion containing schizandrol A are very stable and 
suitable for use. 
The performance of the end products was measured in a Franz diffusion 
cell using a synthetic membrane. All of the nanoemulsion formulations greatly 
enhance the permeation of schizandrol A compared to the control of a 
schizandrol A solution in water/ethanol (50/50, w/w). 
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Despite these achievements, the application of the end product may be 
limited by the low viscosity of the formulation. For transdermal delivery, the 
poor adherence of the end product to the skin can be an issue. Increasing the 
viscosity may broaden the potential application of the formulation and may 
enhance the stability as well.  
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CHAPTER 6 FUTURE WORK 
 
The next step after the success of preparing nanoemulsion containing 
schizandrol A is the toxicity and efficacy testing. The in vivo test usually will 
provide more evidence for the hypothesis that oil-in-water nanoemulsion 
delivery system benefits the absorption of hydrophobic active substance and 
give more information to improve the practical condition. Nonetheless, owing 
to the restrictions on animal testing, in vitro/ex vivo studies can be alternatives 
to in vivo test using animal. 
Ex vivo permeability. The ex vivo permeability of schizandrol A 
nanoemulsion can be evaluated through full thickness human epidermal tissue 
using Franz diffusion cell. The experimental method is similar to in vitro 
permeability study using synthetic membrane. 
Toxicity. The potential cytotoxicity of nanoemulsions in human 
epidermal keratinocytes (HEKs) can be evaluated using viability assay with 
nanoemulsion (no-cell/cell) control (Monteiro-Riviere et al., 2009). The 
toxicity of schizandrol A nanoemulsion to epidermal tissue can be evaluated 
by MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
staining method (Ham et al., 2013). Following the protocol, MTT assays can 
be performed on the tissue after application and the viability of the tissue can 
be calculated. ET50, the time at which 50% of the tissue is still viable can be 
calculated from the dose-response curve. 
Although animal testing is not encouraged, sometimes such testing is 
inevitable for biocompatibility studies. Skin irritation study can be performed 
using rats with hair at abdominal region removed. Formulations can be applied 
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on hair-free side of rats with an adjacent area of untreated skin as a control for 
the test. Signs of erythema and edema are examined and the responses can be 
scored (Draize et al., 1944). 
Nanoemulsion gel can also be prepared to extend the application. The 
viscosity of cosmetic products is typically controlled by changing the amount 
of hydrophilic surfactants or by adding a polymeric thickener. Application of 
gelling agents will provide the nanoemulsion based system with a three-
dimensional gel network, which has a high viscosity and powerful permeation 
ability to delivery schizandrol A though the skin. The systematic screening on 
gelling agents for the formulated system is necessary to ensure the 
compatibility and overall integrity. 
Nutraceuticals are the counterpart of cosmeceuticals. Based on the 
pharmacological properties of schizandrol A, it can be formulated into 
nutraceutical products and functional food/beverages as well. Nutraceuticals 
and functional foods are strong interest in the world market of nutrition and 
food industry. Toxicity will be an important concern for oral administration of 
schizandrol A. In addition, the dissolution and in vivo bioavailability test will 
be essential subsequently. 
Currently, the multi-active substances in lignan group have not yet been 
well developed though they are very promising as potential cosmeceuticals 
and nutraceuticals. The investigation on other schisandra lignans could be 
carried out on the basis of formulation design of schizandrol A as a model 
lignan compound. 
For the cosmeceuticals/nutraceuticals product developed in the lab, a 
scale-up production at lab and small batch is necessary to transfer the 
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approach to industrial application. The scale-up production will give us better 
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Phase Solubility of Schizandrol A in Tween-Based Aqueous Phase 
The solubility of schizandrol A in Tween-based aqueous phases was 
determined. Similar to L1695-based systems, the increase in solubility of 
schizandrol A was expected and the trend followed the previous results on 
solubility capacity (Figure I.1, Figure I.2, and Figure I.3). 
Non-ionic surfactant mixtures hardly show strong synergistic effects due 
to their similar behavior in the aqueous phase. Ethanol greatly facilitated 
Tweens to solubilize schizandrol A while PEG 400 showed limited influence. 
The effect of cyclodextrins on the schizandrol A solubilization followed the 
same trend in L1695/CD mixed systems. 
Solubility capacities of combinations to are listed in Table I.1. 
 
 




Figure I.2 Solubility of schizandrol A in Tween : ethanol (1:1) system. 
 






Figure I.4 Solubility of schizandrol A in Tween : HP-β-CD (1:1) system. 
 




Table I.1 Solubility capacity of Tween-based system for schizandrol A. 
1:1 
Tween 20 Tween 40 Tween 80 
k Standard Error R2 k Standard Error R2 k Standard Error R2 
Tween 20 - - - - - - - - - 
Tween 40 29.632 1.939 0.987 - - - - - - 
Tween 80 35.452 0.147 0.999 36.69 0.971 0.998 - - - 
Ethanol 23.933 2.607 0.965 30.972 1.486 0.993 26.779 0.709 0.998 
PEG 400 16.431 0.078 0.999 18.577 0.636 0.996 18.776 0.636 0.999 
HP-β-CD 12.206 0.203 0.999 16.191 0.167 0.999 18.644 0.610 0.997 





Sucrose Laurate-Based Microemulsions: the Effect of Oil Type on Phase 
Behavior 
Based on phase solubility studies, ethyl butanoate, triacetin, ethyl 
octanoate and oleic acid showed good capacity to solubilize schizandrol A 
(Figure 4.17). Apart from ethyl butanoate, the other three oils were also 
investigated. 
The formation of microemulsion stabilized by sucrose laurate (L1695)-
based emulsifiers has been examined by construction of phase diagrams at 
ambient temperature. Ethanol, propylene glycol and PEG 400 were used as 
cosurfactant. The construction of phase diagrams followed the method 
described in 3.3.3 (Chapter 3) for oleic acid. For triacetin and ethyl octanoate, 
oil titration was used instead of water titration because clear mixture solutions 
cannot be produced at various Ro (oil to emulsifier) weight ratios. 
The greatest difference in phase behaviors was observed in triacetin-based 
systems (Figure II.1). Both cosurfactant and Sm ratio displayed a profound 
impact on the microemulsion zone. A increase in cosurfactant content strongly 
promotes the microemulsion formation especially with high oil content. 
The results suggest that in sucrose laurate based systems, the oil with 
shorter alkyl chain length or smaller molecular volume is solubilized to a 
greater extent than longer chain length or larger molecular volume oils. These 
results are in agreement with similar work done by Warisnoicharoen and 
coworkers (2000) on polyoxyethylene surfactants. The presence of 
cosurfactant is essential for L1695 to form microemulsion. The type of 












Figure II.1 Phase behaviors of L1695-based emulsifiers/triacetin/water 
system containing different cosurfactant at different Sm ratios. Cosurfactant 











Figure II.2 Phase behaviors of L1695-based emulsifiers/ethyl 
octanoate/water system containing different cosurfactant at different Sm ratios. 










Figure II.3 Phase behaviors of L1695-based emulsifiers/oleic acid/water 
system containing different cosurfactant at different Sm ratios. Cosurfactant 







Characterization of Sucrose Laurate-Based Oil-in-Water Nanoemulsion 
Formulation Bases 
 
Nanoemulsion prepared using different emulsifier system, different oil 
concentrations were investigated by the HPH process. The efficiency of HPH 
for nanoemulsion formation largely depends on the oil concentration. With 20 
wt% oil present in the system, transparent nanoemulsion formulation could not 
be obtained by 50 homogenization passes (Table III.1). 
Systems containing 3 wt% emulsifiers/ 10 wt% oil/ 87 wt% water were 
subjected to physicochemical characterization. The results are listed in (Table 
III.2). The microstructure of selected nanoemulsion formulation bases was 
observed by TEM (Figure III.1). There is no obvious difference in shape, size 
and size distribution of these samples from nanoemulsion formulations 
containing schizandrol A. The results suggest that schizandrol A does not 
affect the droplet formation under HPH process. 




Table III.1 Number of homogenization passes needed for preparation of 





Number of passes 
Ethyl butanoate 
concentration (wt%) 
3 wt% 10 15 20 
A1 
L1695/EtOH 
1:2 40 N/A N/A 
A2 1:1 30 50 N/A 
A3 2:1 40 50 N/A 
      
B1 
L1695/PG 
1:2 40 50 N/A 
B2 1:1 40 50 N/A 
B3 2:1 40 50 N/A 
      
C1 
L1695/PEG 400 
1:2 40 N/A N/A 
C2 1:1 40 50 N/A 
C3 2:1 40 50 N/A 
N/A denotes ‘not applicable’ that a transparent nanoemulsion cannot be 
produced under such condition. The HPH process for each formulation 





Table III.2 Physicochemical properties of nanoemulsion formulation bases 







  Refractive 
index (n) 
(σ, µs/cm)     
A1 113.60 ± 1.56 
 
5.60 ± 0.08 
 
1.336 
A2 68.40 ± 0.71 
 
5.39 ± 0.62 
 
1.341 
A3 77.25 ± 0.07 
 
5.44 ± 0.15 
 
1.338 
          B1 78.10 ± 6.22 
 
5.61 ± 0.33 
 
1.339 
B2 94.20 ± 1.98 
 
5.28 
   
1.338 
B3 96.30 ± 0.28 
 
5.06 ± 0.25 
 
1.338 
          C1 134.95 ± 1.06 
 
5.07 ± 0.27 
 
1.338 
C2 84.35 ± 0.21 
 
4.94 ± 0.31 
 
1.339 












Figure III.1 TEM micrographs of nanoemulsion bases for: (i) A2, (ii) B2, 
(iii) C2 containing 10 wt% ethyl butanoate prepared by HPH method (150 
MPa, 50 passes). The length of scale bar is 20 nm for (i) and iii, 50 nm for (ii). 
 
